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Gastrointestinal (GI) smooth muscle possesses distinct regional and functional properties 
that distinguish it from other types of visceral and vascular smooth muscle.  On the basis of 
electrical properties and contractile phenotype, GI smooth muscles have been classified into 
phasic (non-sphinteric) and tonic (sphinteric) smooth muscles. The biochemical basis of phasic 
and tonic phenotypes of smooth muscle is not clear and is the major question of inquiry of the 
present study.  Phosphorylation of Ser
19
 on the 20 kDa myosin light chain (MLC) is essential for 
acto-myosin interaction and contraction in both phasic and tonic muscles.  The levels of MLC20 
xvii 
phosphorylation are regulated by Ca
2+
/calmodulin-dependent MLC kinase (MLCK) and MLC 
phosphatase (MLCP), and the activity of these enzymes are in turn regulated by various signaling 
molecules whose expression and activity are important in determining the strength and duration 
of their activity.  The signaling proteins are AMP kinase (MLCK activity), Rho kinase, zipper-
interacting protein kinase (ZIPK), CPI-17 and telokin (MLCP activity), phosphodiesterase 5 
(PDE5) and multi-drug resistance protein 5 (MRP5).  The overarching goal of the dissertation is 
to identify the differences in the signaling pathways that regulate MLCK and MLCP activities, 
and thus MLC20 phosphorylation and muscle function.  Using biochemical, molecular and 
functional approaches, and antrum (distal stomach) and fundus (proximal stomach) of rabbit 
stomach as models of phasic and tonic smooth muscles, respectively, the present study 
characterized important differences in the signaling pathways that highly correlate with the 
contractile phenotype.  These include: 1) tissue-specific expression of contractile proteins such as 
myosin heavy chain isoforms, actin,  caldesmon, calponin, - and β-tropomyosin, smoothelin-A 
and -B; 2) higher expression of AMPK, selective feedback inhibition of MLCK activity via 
AMPK-mediated phosphorylation, and higher expression of telokin and activation of MLCP 
correlate with the rapid cyclical contractile function in phasic muscle; 3) higher expression and 
activation of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17 pathways, preferential inhibition of 
MLCP activity, and sustained phosphorylation of MLC20 correlate with the sustained contraction 
in tonic muscle; and 4) rapid termination of cGMP signal and muscle relaxation by preferential 
degradation and efflux of cGMP via higher expression of PDE5 and MRP5, respectively, 
correlate with the brief relaxation and rapid restoration of contraction in tonic muscle. It is 
anticipated that these findings could be important in providing the underlying mechanisms 
involved in the pathophysiology of smooth muscle function and new insights for the development 
of therapeutic agents that should act on smooth muscle in the gut to treat motility disorders as 
xviii 
well as in other regions such as airways and vascular smooth muscle where similar intracellular 
mechanisms may prevail. 
CHAPTER 1  
INTRODUCTION AND BACKGROUND 
1 
 
  
1.1       Introduction 
The gastrointestinal (GI) tract is a complex multi-organ system with tissues that differ 
structurally and functionally. The dynamic interactions between the neuronal, muscular, immune, 
and glandular tissues allow the GI tract to perform its main physiological functions, which 
include digestion, absorption, excretion, and protection. Normal gut motility provides for the 
mixing and propulsion of intraluminal contents to enable efficient digestion of food, progressive 
absorption of nutrients, and evacuation of residues. These fine and delicate GI tract movements 
are generated by a highly-regulated interaction between an intricate network of neurons located 
within the wall of the alimentary canal (i.e., the enteric nervous system), an intrinsic pacemaker 
system (i.e., interstitial cells of Cajal or ICC) and the final effector cells (i.e., smooth muscle 
cells).  
1.2       GI tract wall 
GI tract wall is composed of four layers that have morphological and functional 
differences. The four layers, from inside of the gut tube to outside, are the mucosa, the 
submucosa, the muscularis propia and the serosa. The smooth muscle of muscularis propia of the 
gut consists of a thin, outer longitudinal layer and a thick, densely innervated circular layer (and 
another oblique layer in the stomach); the layers derive their names from the orientation of the 
2 
long axis of muscle cells in them. The muscle cells are separated by laminar septa into bundles 
that are embedded in a connective tissue matrix. The muscle layers are separated by neurons, 
glial cells, fibroblasts, and interstitial cells of Cajal (ICC)
1
. 
1.3       GI tract smooth muscle 
GI tract smooth muscle possesses distinct regional and functional properties that 
distinguish it from other types of visceral and vascular smooth muscle. Gut smooth muscles 
contract spontaneously in the absence of neural, humoral, or hormonal stimuli and in response to 
stretch. They contract as a syncytium (i.e., contract in unison) and therefore classified as unitary-
type smooth muscle
2
.  
In general, smooth muscle cells are spindle-shaped of about 400µm in length and 5 to 15 
µm wide. They lack the visible cross-striations seen in other muscle types.  Their plasma 
membranes consist of two specialized structures known as caveolae and dense bands. The 
caveolae are clusters of basket-shaped invaginations of the membrane, the bases of which are 
surrounded by the endoplasmic reticulum (called sarcoplasmic reticulum in smooth muscle).  
Different caveolin proteins bind to a variety of signaling molecules and act as scaffolds to 
facilitate signaling. Clusters of caveolae are separated from each other by electron-dense 
structures called dense bands; the site of attachment of thin actin filaments to transmembrane 
integrins
2
. 
Two types of coupling connect neighboring smooth muscle cells; mechanical coupling 
which is provided by the intermediate junctions - formed by the juxtaposed dense bands from 
adjacent cells, and electrical coupling which is provided by gap junctions (or nexuses). Gap 
junctions are patches of the closely opposed plasma membranes of adjacent cells, the space of 
which is bridged by intercellular channels though which intracellular regulatory molecules like 
Ca
2+
 and cyclic nucleotides are capable of movement between neighboring cells
2
.  
3 
Dense bodies are Z-lines-like structures, from which actin thin filaments emerge and 
interdigitate with myosin thick filaments. Most of the interior space of muscle cell is occupied by 
the contractile filaments and dense bodies while the remainder is occupied by the various 
organelles
2
.  Sarcoplasmic reticulum is located immediately beneath and parallel to plasma 
membrane, and is the site of Ca
2+
 uptake and release
3
. 
1.4       Contractile apparatus; thin and thick filaments 
Three types of filaments can be distinguished in smooth muscle cells: thin actin filaments, 
thick myosin filaments, and intermediate desmin filaments. Intermediate filaments link dense 
bands in the plasma membrane to dense bodies in the cytoplasm
4
. 
Thin filaments consist of actin; a ubiquitous 42 kDa globular protein (G-actin) that 
polymerizes to form 2-stranded helical filaments (F-actin). Inserted in the grooves of the actin 
helix is another protein, tropomyosin.  Thin filaments in smooth muscle have a distinct polarity, 
they insert into and emerge from the dense bodies, and they are arranged in bundles that run 
parallel to the long axis of the cells, with their free ends surrounding and interdigitating with 
thick myosin filaments.  Actin filaments are organized through attachments to the dense bodies 
that contain α-actinin, a Z-band protein in skeletal muscle4. 
 Thick filaments are aggregates of myosin molecules formed from the association of six 
different proteins: one pair of myosin heavy chains (MHCs) and two pairs of myosin light chains 
(MLCs). Myosin II is the molecular motor of muscle cells and the velocity of muscle contraction 
is determined by the ATPase activity of myosin as it interacts with actin
5
.   The heavy chains are 
coiled around each other to form an α-helical core or tail. Each strand of the core terminates in a 
globular head surrounded by two MLCs: a 20 kDa regulatory and phosphorylatable chain 
(MLC20) and a 17 kDa chain. Each globular head contains a binding site for actin and an actin-
activated magnesium-adenosine triphosphatase (Mg
2+
-ATP).  
4 
Hydrolysis of ATP is the fundamental reaction whereby chemical energy is converted into 
mechanical energy in smooth muscle. The reaction generates force or induces shortening as a 
result of the sliding of the overlapping and interdigitating thin and thick filaments. The force 
generated by crossbridge cycling depends on the number of crossbridges acting in parallel. The 
crossbridges do not cycle in unison; thus, in smooth muscle, unlike in striated muscle, both the 
number and the cycling rate of crossbridges are under regulation
6
.  
1.5       The actomyosin crossbridge cycle 
ATP, bound weakly to myosin, is hydrolyzed to ADP and inorganic phosphate (Pi). The 
products of hydrolysis remain bound to the myosin head, and the energy released is stored in the 
myosin molecule, which has a high affinity for actin in this state. The binding of myosin to actin 
can promote a major change in conformation (the power stroke), consisting of a reorientation of 
part of the myosin head distal to the actin-binding site which is accompanied by the dissociation 
of Pi. Upon release of ADP and Pi, ATP binds again to myosin, which then reverts to a state of 
low affinity for actin. Cross-bridge cycling ceases after the stimulus is withdrawn; the 
dephosphorylated myosin cross-bridges are arrested in a detached state, which is characteristic of 
relaxed muscle
7
.  
A unique pattern of crossbridge cycling is observed during sustained (tonic) contraction 
of smooth muscle, in which muscle contraction attains a peak and maintains it near steady state. 
This state has been called the “latch” state which represents a transition from a state of rapidly 
cycling crossbridges to a state of attached non-cycling or slowly cycling crossbridges.  These 
latch bridges maintain force in sustained contraction
7
.  
1.6       Neural regulation of smooth muscle contraction 
The intrinsic electrical and mechanical properties of smooth muscle are modulated by 
neurotransmitters released from neurons of the enteric nervous system, especially neurons of the 
5 
myenteric plexus. Myenteric plexus contains two main types of neurons: one type contains 
inhibitory neurotransmitters such as VIP or PACAP together with NO synthase (NOS), the 
enzyme responsible for synthesis of nitric oxide in the nerve terminals, while the majority of the 
neurons contain excitatory neurotransmitters, mainly acetylcholine, usually together with 
tachykinins; substance P and neurokinin A (NKA), which are released at higher frequencies of 
stimulation
8
.   
Excitatory neurotransmitters stimulate Ca
2+
 release, increase muscle tone, and depolarize 
the plasma membrane (i.e., trigger excitatory junctional potentials or EJPs). The depolarization 
can result from either a direct action of neurotransmitters on muscle cells or may be mediated 
through intramuscular ICC (ICC-IM) which are coupled electrically to muscle cells. EJPs can 
induce Ca
2+
 influx and contraction if the depolarization reaches a level at which voltage-gated 
Ca
2+
 channels open; this is likely to occur in tonic smooth muscle as the membrane potential is 
close to the Ca
2+
 threshold or in phasic smooth muscle during the peak of slow wave activity
4
.  
A large variety of receptors and receptor subtypes have been identified as capable of 
mediating smooth muscle contraction. These include receptors for peptides (e.g., tachykinins, 
endothelin, motilin), amines (histamine, 5- hydroxytryptamine), pyrimidines/purines (UTP and 
ATP), and lipids (S1P, LPA)
9
.  
M2 and m3 receptors are the main muscarinic receptor types expressed in smooth muscle.  
Acetylcholine (ACh) interaction with m3 receptor couples it to Gαq leading to activation of 
phospholipase C (PLC) and hydrolysis of phosphatidyl inositol (PI) into inositol 1, 4, 5-
trisphosphate (IP3) and DAG. IP3 binds IP3 receptors on SR and stimulates Ca
2+
 release and thus 
smooth muscle contraction. ACh interacts also with m2 receptor -the predominant (80%) receptor 
species in smooth muscle- and couples it to Gαi3 leading to inhibition of adenylate cyclase10,11.  
6 
Inhibitory neurotransmitters, on the other hand, inhibit Ca
2+
 release, decrease muscle tone 
(i.e., relax), and hyperpolarize the plasma membrane directly or indirectly via ICC-IM (i.e., 
trigger inhibitory junctional potentials or IJPs). IJPs lower the plateau potential of slow waves 
and inhibit Ca
2+
 influx and phasic contraction
4
.  
VIP or PACAP induce relaxation by interacting with VPAC2 receptors, which possess 
equal affinity for VIP and PACAP. These receptors couple to Gs and thereby lead to activation of 
adenylate cyclase (AC) which increases cAMP generation and thus PKA activation. Nitric oxide 
activates soluble guanylate cyclase (sGC) which increases cGMP formation, and thus leads to 
activation of PKG. Both kinases (PKA and PKG) act in conjunction to cause hyperpolarization 
and relaxation of smooth muscle cells
12
.  
1.7      Role of ICC in smooth muscle contraction 
ICC are mesenchymal cells, interposed between enteric nerves and smooth muscle cells, 
with small cell bodies and several elongated processes and are classified based on their location 
and distribution
13
. They express c-kit, the proto-oncogene that encodes the receptor tyrosine 
kinase, kit
14
. Myenteric ICC (ICC-MY) reside between the longitudinal and circular muscle 
layers in the myenteric region. These cells are important as pacemakers; they are spontaneously 
active and generate slow wave depolarization in different parts of the GI tract
15
. Another group of 
ICC has an intramuscular location (ICC-IM) with individual ICC being distributed in between 
smooth muscle cells. Other morphologically similar ICC are located in the deep muscular plexus 
of the small intestine (ICC-DMP). ICC-IM and ICC-DMP are found to be interposed between 
nerve terminals and smooth muscle cells and closely associated with neuronal processes
16
. In 
addition, slow waves are modified by other substances such as hormones, paracrine substances, 
7 
and inflammatory mediators. It is not clear yet if these substances have sites of action on ICC-
IM
17
. 
The amplitude of the slow wave and the resultant contractile force are regulated by the 
enteric nervous system. An excitatory neural input (i.e., release of acetylcholine or tachykinins) 
increases the amplitude and duration of the plateau potential of slow waves, which then increases 
Ca
2+
 entry and enhances force of contraction. Spike potentials can be superimposed on plateau 
potential and further augment intracellular Ca
2+
 level (or [Ca
2+
]i) and muscle contraction. On the 
other hand, an inhibitory neural input (i.e., release of NO, VIP, or PACAP) activates K
+
 channels 
and suppresses inward current conductance in smooth muscle cells, which thereby reduces the 
amplitude of slow waves and attenuates contractile force
18
.  
In rhythmic GI tract parts (e.g., antrum part of the stomach), slow waves -generated by 
ICC-MY- depolarize smooth muscle cells to induce the opening of voltage-dependent L-type 
Ca
2+
 channels. The electrical activity of slow waves is propagated through networks of ICC and 
conducted passively to smooth muscle cells through gap junctions. These low-resistance 
connections between ICC and smooth muscle cells facilitate the propagation of electrical events 
from one cell to another
4
.  
The regulation of muscle tone (e.g., fundus part of the stomach which is devoid of ICC-
MY), however, is not mediated by changes in smooth muscle membrane potential or slow wave 
generation but by signaling cascades initiated mainly by enteric neurotransmitters acting directly 
on smooth muscle receptors or indirectly via ICC-IM
4
.   
1.8       Peristalsis  
Peristalsis is a distinctive pattern of smooth muscle contraction that propels foodstuffs 
distally through the GI tract. It was first described by Bayliss and Starling as a type of motility 
8 
wholly mediated by the enteric nervous system in which there is contraction above and relaxation 
below the segment being stimulated
19
. It can be evoked by stroking, initiated by the release of 
serotonin (5-HT) from mucosal enterochromaffin cells which acts upon 5-HT receptors of enteric 
sensory nerve terminals in mucosa causing the release of the sensory neurotransmitter calcitonin 
gene-related peptide (CGRP)
20
. Peristalsis can also be elicited by radial stretch, which activates 
the intramuscular nerve terminals of extrinsic sensory neurons which have axonal projections to 
myenteric neurons
21
.  
Peristaltic reflex consists of an ascending and descending phases. During the descending 
phase, circular muscle relaxes and longitudinal muscle contracts, while during the ascending 
phase, circular muscle contracts and longitudinal muscle relaxes. This reciprocal contraction and 
relaxation of the two muscle layers maintain the dimensions of the segment. VIP, PACAP, and 
NO are released during and responsible for the descending relaxation of circular muscle, while 
acetylcholine, substance P, and NKA are released during and responsible for the ascending 
contraction of circular muscle
22
. 
1.9      Signaling for smooth muscle contraction 
An essential step in smooth muscle contraction is phosphorylation of the 20 kDa 
regulatory myosin light chain (MLC20) by a Ca
2+
/calmodulin-dependent or -independent myosin 
light chain kinase (MLCK) which transfers the phosphate group from ATP to either Ser
19
 or Thr
18
 
hydroxyl groups of MLC20. This phosphorylation activates the actin-activated myosin ATPase 
and actin-myosin interaction, which thereby initiates smooth muscle contraction.  
An increase in intracellular free Ca
2+
 concentration induces activation of Ca
2+
/CaM-
dependent MLCK and the phophorylation of MLC20 and thus muscle contraction. The decrease in 
intracellular level of Ca
2+
 induces dissociation of the Ca
2+
-CaM-MLCK complex, resulting in 
9 
dephosphorylation of the MLC20 by myosin light chain phosphatase (MLCP) and thus smooth 
muscle relaxation
9,23
. Thus, the phosphorylation level of MLC20 is determined by the opposing 
activities of MLCK and MLCP and both of these enzymes‟ activities are well-regulated in 
smooth muscle. 
1.9.1    MLCK regulation 
As mentioned previously, smooth muscle tone is regulated by signaling cascades initiated 
by enteric neurotransmitters acting directly on smooth muscle receptors. In circular smooth 
muscle cells, contractile agonists activate PLC-β1 via Gαq coupled receptors (e.g., muscarinic m3 
receptors) by Gαq binding to PLC-β1‟s COOH-terminal tail24. PLC-β1 hydrolyzes PIP2 into 
DAG and IP3. An increase in IP3 leads to the binding of IP3 to the high affinity IP3 
receptor/Ca
2+
 channel on the sarcoplasmic reticulum, resulting in the release of Ca
2+
 into the 
cytosol. Of the two IP3 receptor isoforms (IP3R-I and IP3R-III) expressed in smooth muscle 
cells, only IP3R-I mediates Ca
2+
 release
25
. 
In longitudinal smooth muscle cells, Ca
2+
 mobilization is dependent on a mandatory step 
involving Ca
2+
 influx via voltage-gated Ca
2+
 channels
25
. Upon contractile agonist stimulation, 
both Gq- and Gi-coupled receptors activate cytoplasmic PLA2 resulting in phosphatidylcholine 
hydrolysis into arachidonic acid which induces membrane depolarization and opening of voltage-
gated Ca
2+
 channels. The entry of Ca
2+
 stimulates cyclic ADP ribose formation and induces 
synergistic Ca
2+
- and cyclic ADP ribose-induced Ca
2+
 release via ryanodine receptors/Ca
2+
 
channels
26
. 
MLCK activity is strictly dependent on [Ca
2+
]i which, upon agonist stimulation, increases 
as a result of Ca
2+
 influx into the cytosol through voltage-gated channels and/or the release of 
Ca
2+
 from intracellular stores. Resting levels of [Ca
2+
]i (70-100nM) increases up to 8-fold during 
maximum contraction.  
10 
Four Ca
2+
 ions bind to calmodulin (CaM) cofactor which then binds to and activates 
MLCK
27
. The transient high levels of [Ca
2+
]i are then extruded from the cell and/or up taken into 
the sarcoplasmic Ca
2+
 stores. This decrease in the intracellular level of Ca
2+
 induces dissociation 
of the Ca
2+
-CaM-MLCK complex, which thereupon decreases MLCK activity. MLC20 
phosphorylation and contraction, however, are maintained by Ca
2+
-independent MLCKs and 
regulated inhibition of MLCP activity in a process called Ca
2+
 sensitization
23
.  
Moreover, MLCK activity was shown to be regulated by protein kinases that act to 
provide negative feedback mechanisms. Stull and coworkers have found that MLCK is 
phosphorylated by CaMKII, and this phosphorylation decreases the activity of MLCK by 
decreasing the affinity of the enzyme for calmodulin. It was found that [Ca
2+
]i required for the 
half-maximum activation of CaMKII equals 500 nM, whereas that for MLCK activation is only 
250 nM, suggesting a role for CaMKII in inactivation of MLCK when smooth muscle is 
hyperactivated and [Ca
2+
]i rises above some critical level
28
. A similar mechanism has been 
proposed recently with AMP kinase (AMPK) in which AMPK phosphorylates MLCK at Ser
815 
leading to decreased activity of MLCK. It was found that ablation of AMPK augmented 
contraction, suggesting rapid MLCK attenuation and suppression of contraction by AMPK
29
. In 
addition, p21-activated protein kinase 1 (PAK1) was shown to attenuate smooth muscle 
contraction by phosphorylating and inactivating MLCK
30
.  
1.9.2    MLCP regulation 
While MLCK-mediated contraction is strictly dependent on [Ca
2+
]i, agonist-induced 
MLC20 phosphorylation and contraction can be maintained even after [Ca
2+
]i returns to basal 
levels via two ways; MLC20 phosphorylation by Ca
2+
-independent MLCKs and regulated 
inhibition of MLCP.   
11 
An important step in maintaining contraction via MLCP inhibition involves activation of 
RhoA via a cascade leading to sequential agonist-mediated activation of Gq/Gα13 and Rho 
guanine nucleotide exchange factor (Rho-GEF) 
30,31
. Activated Rho A (Rho-GTP) is translocated 
to the plasma membrane where it activates both Rho kinase -mainly Rho kinase II, the 
predominant smooth muscle isoform- and PLD
32
. Hydrolysis of phosphatidylcholine by PLD 
yields phosphatidic acid, which is dephophorylated to diacylglycerol, resulting in sustained 
activation of Ca
2+
-dependent and -independent PKC isozymes. Rho kinase and PKC act 
concurrently and cooperatively to inhibit MLCP activity
9
. 
The same receptors that initiate Ca
2+
 mobilization and MLCK-mediated MLC20 
phosphorylation and contraction also engage a distinct G protein-dependent pathway that 
mediates Ca
2+
-independent MLC20 phosphorylation and contraction via negative regulation of 
MLCP.  Some receptors (e.g., m3 receptors) are coupled to RhoA via G13 only, whereas others 
(e.g., SIP2 and motilin receptors) are coupled to RhoA via both Gq and G13
30,33,34
. 
Structurally, MLCP holoenzyme consists of three subunits; a 37 kDa catalytic subunit of 
type 1 phosphatase (ppicδ), a 110 to 130 kDa regulatory subunit, known as myosin phosphatase 
target subunit I or MYPT1, and a 20 kDa subunit of unknown function. MYPT1 binding to the 
catalytic subunit enhances MLCP catalytic activity
35
. 
Phosphorylation of MYPT1 at Thr
696
 by Rho kinase promotes dissociation of the catalytic 
and regulatory subunits of MLCP and inhibits its catalytic activity 
36
. Rho kinase also 
phophorylates Thr
853
 within the myosin-binding domain on MYPT1 upon which the enzyme 
dissociates from myosin and decreases the efficiency of the enzyme by decreasing availabilty of 
the substrate
31
. On the other hand, phosphorylation of an adjacent Ser
695
 by cAMP- or cGMP-
dependent protein kinase (PKA and PKG, respectively) blocks the ability of Rho kinase to 
phosphorylate Thr
696
 and so restores MLCP activity 
37
. 
12 
PKC, mainly PKC-ε and PKC-δ, phosphorylates CPI-17, a 17 kDa endogenous inhibitor 
of MLCP, at Thr
38
 and greatly enhancing its ability to inhibit MLCP 
38
. Thus, a dual Rho-
dependent mechanism (i.e., via Rho kinase and PKC activation) causes sustained inhibition of 
MLCP. The relative involvement of Rho-mediated pathways-Rho kinase/MYPT1 and PKC/CPI-
17- in MLCP inhibition appears to be receptor-specific. Most Gq/13-coupled receptors (e.g., m3, 
S1P2, motilin) engage both pathways. ETA receptors engage only Rho kinase/MYPT1 while 
LPA3 receptors engage only PKC/CPI-17
33,34,39,40
. 
Zipper interacting protein kinase (ZIPK) was also found to inhibit MLCP. It is a 
serine/threonin kinase expressed in various tissues including smooth muscle and is a member of 
the death–associated protein kinase (DAP) family41. ZIPK co-localizes with MLCP and is 
phosphorylated following activation of Rho kinase-dependent pathway during carbachol 
stimulation of rabbit bladder. The phosphorylated ZIPK, in turn, phosphorylates the myosin-
binding subunit at Thr
696
, considerably faster and even more effective than Rho kinase
42,43
. Niiro 
and Ikebe, however
44
, have demonstrated that MYPT1 is a poor substrate for ZIPK, and instead, 
ZIPK acts as a Ca
2+
-independent MLCK that directly phosphorylates MLC20 at both Ser
19
 and 
Thr
18
 in absence of Ca
2+
. It has been suggested that the myofilament-bound ZIPK may mediate 
Rho kinase–dependent phosphorylation of MYPT1 and inhibition of MLCP and thus could be the 
link between the activated plasma membrane-bound Rho kinase and MYPT1. 
Integrin-linked kinase (ILK) is another myofilament-bound Ca
2+
-independent MLCK. It 
mediates MLC20 phosphorylation, at both Ser
19
 and Thr
18
, and smooth muscle contraction 
through Gi-coupled receptors. These receptors sequentially activate ILK through certain pathway 
involving PI3-kinase activation via Gβγi45. 
1.10     Regulation of smooth muscle contractility by thin filament-associated proteins 
13 
The thin filaments are defined as those filaments 6–8 nm in diameter and composed of 
filamentous actin. They are different from the intermediate filaments (10 nm), the myosin 
filaments (15-18 nm), and the microtubules (~24 nm)
46
. Some proteins have been suggested to 
bind actin and possibly regulate smooth muscle contraction. Thin filament-associated proteins 
include: Tropomyosin (Tm), caldesmon (CaD), calponin (CaP), and smoothelin. 
1.10.1  Tropomyosin (Tm) 
Tm is a coiled-coil α-helix that spans seven actin monomers. Individual molecules 
interact head to tail, thereby creating a continuous strand along the actin filament
47
. Functionally, 
X-ray and fluorescent resonance energy transfer studies have shown that activation of smooth 
muscle leads to movement and displacement of Tm away from actin monomers, i.e., exposing 
myosin-binding sites on actin for myosin binding and thus forming cross-bridges
48,49
. Moreover, 
Tm is necessary for full inhibition of actomyosin ATPase activity by CaD
50
. Two Tm isoforms 
appear to be specific to smooth muscle; α-Tm and β-Tm. PKC-mediated phosphorylation and 
displacement of TM is associated with smooth muscle contraction by enhancing the cooperative 
activation of actomyosin
51
.  
1.10.2  Calponin (CaP) 
Calponin was first found in smooth muscle cells as a striated muscle troponin-like protein 
with a proposed function in the regulation of smooth muscle contraction
52
. Calponin is now well-
known as a family of actin filament-associated proteins of 34-37 kDa expressed in both smooth 
muscle and non-muscle cells.  Three isoforms of calponin have been found in the vertebrates as 
the products of three homologous genes
53
; a basic calponin (h1-calponin), which is the chicken 
gizzard calponin ortholog, a neutral calponin (h2-calponin), and an acidic calponin (h3-calponin). 
h1-calponin is specific to differentiated smooth muscle cells and up-regulated during post-natal 
development, while both h2 and h3-calponins are expressed in both muscle and non-muscle 
14 
tissues
54
. There is an in vitro experimental evidence that calponin inhibits actin-activated myosin 
ATPase
55
.   
In vitro phosphorylation of CaP (most probably at Ser
175
 and Thr
184
) by several kinases 
(such as PKC-ε) resulted in the loss of its ability to bind F-actin to inhibit both actomyosin Mg2+-
ATPase activity
56
 and unloaded shortening velocity
57
. 
1.10.3  Caldesmon (CaD) 
Caldesmon is another actin-binding protein that is present in both smooth muscle and 
non-muscle cells. The heavier smooth muscle isoform (h-caldesmon, 87 kDa) is found in 
differentiated „contractile‟ smooth muscle cells, whereas the lighter isoform (i-caldesmon, 57 
kDa) is expressed in both non-muscle cells and „synthetic‟ smooth muscle cells58. Caldesmon 
binds myosin, actin, tropomyosin, and calmodulin and inhibits the actin-activated myosin 
ATPase by blocking the interaction of actin and myosin
59
 and/or inhibiting a kinetic step of the 
actomyosin ATPase cycle
60
. Inhibition of contraction by caldesmon can be released by its 
binding to Ca
2+
/calmodulin
61
 or via posttranslational phosphorylation at Ser
789 62
. 
Immunocytochemical studies of chicken gizzard smooth muscle have revealed that CaD is 
colocalized with contractile proteins, while CaP is associated with both contractile and 
cytoskeletal proteins
63
. 
1.10.4  Smoothelin 
Smoothelins are smooth muscle α actin stress fibers-binding proteins that are specifically 
and abundantly expressed in contractile smooth muscle cells, absent or limited in non-contractile 
and proliferative smooth muscle cells or cells with smooth muscle-like features, and are the only 
marker that differentiates between smooth muscle cells and myofibroblasts
64
. They are encoded 
by a single-copy gene via dual promoter system that generates two major isoforms containing a 
troponin T-like domain; A (59 kDa) and B (110 kDa) isoforms
65
. Lack of smoothelin-A, the main 
15 
isoform in visceral smooth muscle, decreases intestinal contractions in response to both receptor-
mediated (e.g., ACh) and non receptor-mediated contractile agonists (e.g., KCl), but the 
mechanism of regulation is yet unknown
66
.     
1.11     Signaling for relaxation 
Smooth muscle relaxation is initiated by targeting MLC20 dephosphorylation. This 
involves either MLCK inactivation and/or removal of MLCP inhibition. Most agents cause 
relaxation by stimulating the production of cAMP (e.g., VIP and its homologue PACAP) or 
cGMP (e.g., nitric oxide [NO]) leading to activation of PKA, PKG or both. Cyclic AMP-
activated PKA and cGMP-activated PKG are the main enzymes that induce relaxation in smooth 
muscle. They target different components of the contractile signaling pathways that attenuate 
MLCK activity and/or augment MLCP activity which eventually induce dephosphorylation of 
MLC20 and thus smooth muscle relaxation
9
. 
1.11.1 Cyclic nucleotide regulation: 
The levels of cAMP and cGMP in gastrointestinal smooth muscle depend on the rates of 
their synthesis by cyclases and degradation by phosphodiesterases (PDEs). Cyclic AMP, which is 
produced in ~10-fold greater amounts than cGMP, is generated from ATP via the membrane-
bound adenylate cyclase (AC) -type V and VI- and is rapidly degraded by the cAMP-preferring 
PDE3 and cAMP-specific PDE4. On the other hand, cGMP is generated from GTP via the 
soluble guanylate cyclase (sGC) and is rapidly degraded by cGMP-specific PDE5.  PKA inhibits 
AC while PKG inhibits sGC. Both PDE3 and PDE4 are activated by PKA, but only PDE3 is 
inhibited by cGMP. On the other hand, PDE5 is activated by PKG. When both cAMP and cGMP 
are present, PDE5 is also activated by PKA
67-69
. So, regulatory feedback from the protein kinases 
inhibits synthesis and accelerates degradation, and thereby maintains the levels of cyclic 
nucleotides within a narrow range.  
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Although cAMP preferentially activates PKA, it can, at higher concentrations, also cross-
reactivate PKG
70
. An increase in both cAMP and cGMP, such as that brought about by corelease 
of NO, VIP, and PACAP from the same or adjacent nerve terminals, is the physiological norm 
during nerve-induced relaxation of the gut. Inhibition of PDE3 by cGMP enhances cAMP levels, 
whereas activation of PDE5 by PKA and PKG greatly increases its affinity for the more abundant 
cAMP. Under these conditions, PKG is activated by both cGMP and cAMP 
69,71
. 
In addition to degradation by phosphodiesterases, cyclic nucleotides elimination pathways 
comprise active export into the extracellular space via members of the multidrug resistance 
protein (MRP) family (the other name is ABC transporters). MRPs bind and hydrolyze ATP, 
providing the energy to transport their substrates across membrane barriers. Among the MRP 
family membes, MRP4 and MRP5 have been shown to be competent in the transport of cAMP 
and cGMP respectively
72
. 
1.11.2  PKA and PKG targets 
PKA and PKG indirectly target MLCK inactivation by primarily decreasing [Ca
2+
]i. Both 
PKA and PKG can inhibit Ca
2+
 mobilization by inhibiting IP3 formation in circular muscle and 
arachidonic acid formation in longitudinal muscle. Inhibition of IP3 formation in circular muscle 
involves phosphorylation of RGS4, leading to more rapid degradation of Gαq-GTP and inhibition 
of PLC-β1 activity. PKG-mediated phosphorylation of SERCA2 and sarcoplasmic reticulum IP3 
receptors accelerates Ca
2+
 reuptake into the stores and inhibits IP3-induced Ca
2+
 release, 
respectively. In addition, both kinases inhibit the activity of membrane Ca
2+
 channels and 
stimulate the activity of membrane K
+
 channels, leading to hyperpolarization of the plasma 
membrane and interruption of Ca
2+
 influx into the cell, a mechanism that is important in relaxtion 
of rhythmic contraction
9
. 
17 
Moreover, PKG and PKA augment MLCP activity by different ways; first, they 
phosphorylate the activated form of RhoA (Rho-GTP) at Ser
188
 leading to its inactivation and 
translocation back to the cytosol 
73
. Second, both enzymes can phosphorylate MYPT1 at Ser
695
, 
preventing the inhibitory regulation of Rho kinase-mediated phosphorylation of MYPT1 at Thr
696
 
37
. Finally, both kinases are able to phosphorylate (at Ser
13
) and enhance the activity of telokin, a 
smooth muscle-specific endogenous activator of MLCP 
74
. 
1.12     Phasic and tonic smooth muscles 
Based on the membrane properties, activation speed and contractile behavior, smooth 
muscles have been classified as either phasic or tonic
23
.  Phasic muscles, like those in the distal 
stomach (or antrum), ileum, and taenia coli, generate action potentials, shorten rapidly, and 
typically produce spontaneous and rapid contractions and do not maintain force for extended 
periods of time. These muscles exhibit variable tones on which are superimposed rhythmic or 
phasic contractions driven by cycles of membrane depolarization and repolarization known as 
slow waves, which are believed to be generated by ICC. Tonic smooth muscles, on the other 
hand, do not generate action potentials or spontaneous contractions, but are specialized to 
contract slowly and maintain contractile force for long durations. Examples of tonic smooth 
muscles include proximal stomach (or fundus), sphincters, and gall bladder
9
. 
The phasic and tonic behavior of smooth muscles may also be related to differences in 
content and isoform composition of contractile proteins and intracellular signaling molecules that 
regulate the activities of myosin light chain kinase (MLCK) and myosin light chain phosphatase 
(MLCP).  For example, previous studies have shown that phasic muscle differs from the tonic 
muscle in the relative abundance of the ratio of acidic to basic isoforms of the 17 kDa essential 
light chain and the seven amino acid-inserted to non-inserted myosin heavy chain isoforms 
(SMA/SMB isoforms)
75,76
.   
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MLCK activity is stimulated by an increase in Ca
2+
 via Ca
2+
/calmodulin complex, and 
inhibited by Ca
2+
/calmodulin-dependent protein kinase II in a feedback mechanism.  Moreover, 
recent studies have shown that smooth muscle contraction is attenuated by phosphorylation and 
inactivation of MLCK via AMP-dependent kinase (AMPK).   MLCP activity is inhibited via 
PKC-mediated phosphorylation of the endogenous inhibitor CPI-17, and activated via PKA- and 
PKG-dependent phosphorylation of the endogenous activator telokin.   PKA and PKG are the two 
main kinases responsible for smooth muscle relaxation by targeting different components in the 
signaling pathways of MLCK and MLCP. They are activated by an elevation in cAMP and 
cGMP respectively, the level of which is dependent on the balance between their generation by 
cyclases and degradation by phosphodiesterases.  
It is not known, however, whether the expression and regulation of the signaling 
molecules that regulate MLCK and MLCP are different in phasic and tonic smooth muscle.  The 
purpose of our study is to comprehensively compare the content and regulation of the different 
signaling molecules that regulate MLCK and MLCP as well as highlighting the differences in the 
contractile and thin-filament associated proteins in phasic versus tonic smooth muscle of the 
gastrointestinal tract.  
1.13     Stomah”proximal vs. distal” 
The purpose of this study is to comprehensively compare the content and regulation of 
different contractile proteins and signaling pathways that regulate MLCK and MLCP activity in 
phasic versus tonic smooth muscle of the gastrointestinal tract as well as highlighting other 
aspects of general significance in smooth muscle physiology.  This thesis explores these 
differences in the antrum (represents phasic smooth muscles) versus the fundus (represents tonic 
smooth muscles) parts of the stomach, and so, I found it valuable to have some physiological 
19 
anatomy and membrane potential characteristics of the stomach and brief description of some 
gastric disorders that are related to the improper smooth muscle function in this organ. 
The main motor function of the stomach is to serve as an active reservoir that stores and 
mixes ingested food as well as modulates its rate of emptying into the duodenum. Stomach is 
divided into two major functional areas; the proximal stomach and the distal stomach. The 
proximal stomach consists of the fundus and the upper body (or corpus). The primary function of 
the proximal stomach is to accommodate ingested food. The distal stomach consists of the lower 
body and the antrum. The primary function of distal stomach is to regularly push digested food 
into the duodenum in a well-coordinated fashion
77
.  
The membrane potential of gastric smooth muscle exhibits a characteristic gradient 
decreasing from −48 mV in the fundus to −71 mV in the antrum78. Unlike the distal stomach, the 
proximal stomach membrane potential does not demonstrate phasic changes in potential, in other 
words it is electrically quiescent (without slow waves). Consequently, under basal conditions, the 
fundus exhibits tone rather than pulsation which, in turn, can be modulated by small changes in 
neural and hormonal inputs
79
. Fundus is suitable for receiving (i.e., vagal-mediated receptive 
relaxation) and discharging (i.e., tonic contraction) a meal upon inhibitory (hyperpolarizing) or 
stimulatory (depolarizing) inputs respectively. 
It is believed that corpus is the site of spontaneous pacemaker activity or slow wave 
generation in the stomach
80
. Slow waves originating in the corpus paropagate to and pace antral 
muscle. Unlike the fundus, the distal body of the stomach and the antrum exhibit phasic rather 
than tonic motor activity. This is often seen on endoscopy as a powerful ring-shaped peristaltic 
wave, which initiates in the mid to distal body of the stomach, picking up strength as it drives 
towards the pylorus where it abruptly terminates
81
. As contractions or electrical activity 
corresponding to contractions reach pylorus, the pylorus begins to open or relax. 
20 
 The frequency and direction of the phasic motor activity are tightly coupled with the 
gastric slow wave generated by phasic depolarization of the interstitial cells of Cajal
82
. A slow 
wave frequency of three cycles per minute is present during both the resting and active phases of 
gastric motor activity. Neurohumoral activators increase the slow wave amplitude and this 
initiates a coupled peristaltic response that grinds and triturates food into a fine particulate 
suspension, ready for passage into the duodenum
83
. 
In a number of disease states or conditions, these peristaltic contractions of the stomach 
and/or the opening and closing of the pylorus is irregular. Gastroparesis or delayed gastric 
emptying may result in insufficient contractions to churn food, move food through the pylorus, 
and/or open the pylorus, resulting in gastro retention of food
84
. In another motility disorder 
known as dumping syndrome, the stomach empties at an abnormally high rate into the small 
intestine causing various gastrointestinal disorders
84
. 
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Although, the initial classification was based on membrane properties and contractile 
behavior, recent studies suggests that these muscle types exhibit differences in several cellular 
properties, from membrane activation, cell signaling to the actin-myosin interaction.  Previous 
studies suggest that the phasic and tonic behavior of smooth muscles may be related to 
differences in content and isoform composition of contractile proteins.  Understanding the 
differences in the signaling pathways that regulate MLCK and MLCP activities and cGMP levels 
using biochemical, molecular and functional approaches, and antrum (distal stomach) and fundus 
(proximal stomach) of rabbit stomach as models of phasic and tonic smooth muscle, respectively, 
is the major question of inquiry of the present study.  An understanding of the mechanisms that 
regulate tone and relaxation at the intracellular levels is important in the pathophysiology and 
may provide new insights for the development of therapeutic agents that should act on smooth 
muscle in the gut to treat motility disorders as well as in other regions such as airways and 
vascular smooth muscle where similar intracellular mechanisms may prevail.  
To understand the biochemical basis of phasic and tonic contractile phenotype, I have 
undertaken a systematic analysis of signaling proteins whose expression and activity are 
important in the regulation of MLCK and MLCP activity and cGMP levels.  The signaling 
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proteins are AMPK (MLCK activity), Rho kinase, ZIP, CPI-17 and telokin (MLCP activity) and 
PDE5 and MRP5 (cGMP levels).  
HYPOTHESIS AND SPECIFIC AIMS 
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The following are the Specific Aims and underlying hypotheses. 
Specific Aim 1:  Identification of differences in the signaling pathways mediating 
termination of MLCK activity and muscle contraction. 
Hypothesis.  Expression and function of AMPK-dependent pathway involved in the 
termination of Ca
2+
/CaM-dependent MLCK activity are higher in phasic muscle than tonic 
muscle.  
Specific Aim 2:  Identification of differences in the signaling pathways mediating MLCP 
inhibition and sustained muscle contraction. 
Hypothesis.  Expression and function of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17 
pathways involved in the suppression of MLCP activity are higher in tonic muscle than phasic 
muscle.  
Specific Aim 3:  Identification of differences in the signaling pathways mediating 
termination of cGMP signaling and muscle relaxation. 
Hypothesis.  Expression and function of cGMP degradation (PDE5) and efflux (MRP5) 
are higher in tonic muscle than phasic muscle. 
CHAPTER 2  
MATERIALS AND METHODS 
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2.1       Materials 
[
125
I]cGMP, [-32P]ATP, and [32P]Pi were obtained from PerkinElmer Life Sciences, 
Boston, MA; Collagenase CLS type II and soybean trypsin inhibitor were obtained from 
Worthington, Freehold, NJ; Western blotting, Dowex AG-1 X 8 resin (100-200 mesh in formate 
form), chromatography material and protein assay kit, Tris-HCl Ready Gels were obtained from 
Bio-Rad Laboratories, Hercules, CA; antibodies to MLCK, AMPK, Rho kinase II, PKC-ε, ZIPK, 
telokin, CPI-17, PDE5,  MYPT1, phospho-MLC20, α-actin, smoothelin, tropomyosin, caldesmon, 
calponin-1, and MRP5 were obtained from Santa Cruz biotechnology, Santa Cruz, CA; myelin 
basic protein (MBP) was obtained from Upstate Biotechnology; Y27632, STO609, Phorbol 12-
myristate 13-acetate (PMA), cGMP, PKI(6-22) amide  were obtained from Calbiochem, La Jolla, 
CA; RKRSRAE  was obtained from Peninsula Laboratories, Belmont, CA; RNAqueous
TM
 kit was 
obtained from Ambion, Austin, TX; Effectene Transfection Reagent, QIAEX®II Gel extraction 
Kit and QIAprep®Spin Miniprep Kit were obtained from QIAGEN Sciences, Maryland; PCR 
reagents were obtained from Applied Biosystems, Roche; SuperScript
TM
 II Reverse Transcriptese 
and TOPO TA Cloning® Kit  Dual Promoter were obtained from Invitrogen, CA; Dulbecco‟s 
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modified Eagle‟s medium (DMEM) was obtained from Fisher Scientific. All other chemicals 
were obtained from Sigma, St. Louis, MO. 
New Zealand white rabbits (weight: 4-5 lbs) were purchased from RSI Biotechnology, 
Clemmons, NC and killed by injection of euthasol (100 mg/kg), as approved by the Institutional 
Animal Care and Use Committee of the Virginia Commonwealth University. The animals were 
housed in the animal facility administered by the Division of Animal Resources, Virginia 
Commonwealth University.  All procedures were conducted in accordance with the Institutional 
Animal Care and Use Committee of the Virginia Commonwealth University.   
2.2       Methods 
2.2.1    Collection of tissue 
Rabbits were sacrificed by injection of Euthasol (100 mg/kg body weight) into the ear 
vein. The stomach was rapidly removed, emptied of its contents and placed in a cold smooth 
muscle buffer with the following composition: NaCl 120 mM, KCl 4 mM, KH2PO4 2.6 mM, 
CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2-hydroxyethylpiperazine-N‟ 2-ethanesulfonic acid) 
25 mM, glucose 14 mM, and essential amino mixture 2.1% (pH 7.4)
85-87
. 
2.2.2    Preparation of dispersed gastric smooth muscle cells 
Smooth muscle cells from the circular muscle layer of the antrum and fundus were 
isolated by sequential enzymatic digestion of muscle strips, filtration, and centrifugation as 
described previously 
32,85-87
. The tissue was cut into thin slices using a Stadie-Riggs tissue slicer 
and then the slices were incubated for 30 min in a smooth muscle buffer at 31C containing 0.1% 
collagenase (300 U/ml) and 0.01% soybean trypsin inhibitor (w/v). The tissue was continuously 
gassed with 100% oxygen during the entire isolation procedure.  The partly digested tissues were 
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washed twice with 50-ml of collagenase-free smooth muscle buffer and the muscle cells were 
allowed to disperse spontaneously for 30 min in collagenase-free medium. Cells were harvested 
by filtration through 500 μm Nitex and centrifuged twice at 350 g for 10 min to eliminate broken 
cells and organelles. The cells were counted in a hemocytometer and it is estimated that 95% of 
the cells excluded trypan blue.  The experiments were done within 2-3 h of cell dispersion.  
2.2.3    Permeabilization of smooth muscle cells 
Dispersed muscle cells were permeabilized by incubation for 10 min with 35 µg/ml of 
saponin in a medium containing 20 mM NaCl, 100 mM KCl, 5 mM MgSO4, 1 mM NH2PO4, 25 
mM NaHCO3, 0.34 mM CaCl2 and 1 mM EGTA with 1% bovine serum albumin
25
. The cells 
were centrifuged at 350 g for 5 min, washed free of saponin, and resuspended in the same medium 
with 1.5 mM ATP and ATP-regenerating system (5 mM creatine phosphate and 10 U/ml creatine 
phosphokinase). 
2.2.4    Preparation of cultured gastric smooth muscle cells 
Dispersed muscle cells isolated from the antrum and fundus were resuspended in DMEM 
containing penicillin (200 U/ml), streptomycin (200 g/ml), gentamycin (100 g/ml), 
amphotericin B (2.5 g/ml) and 10% fetal bovine serum (DMEM-10).  The muscle cells were 
plated at a concentration of 5 X 10
5
 cells/ml and incubated at 37C in a CO2 incubator.  DMEM-
10 medium was replaced every three days for 2-3 weeks until confluence was attained.  The 
muscle cells in confluent primary cultures were trypsinized (0.5 mg trypsin/ml), re-plated at a 
concentration of 2.5 X 10
5
 cells/ml and cultured under the same conditions.  All experiments were 
done on cells in the first passage.  Previous studies have determined the purity of cultured muscle 
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cells with smooth muscle-specific -actin88. Cultured muscle cells were starved in serum-free 
medium for 24 hours before each use.  
2.2.5   Expression of MRP5, α-actin, β-actin, γ-actin, and myosin isoforms (SM1, SM2, SMA, 
SMB) by RT-PCR  
  Total RNA was isolated from freshly dispersed smooth muscle cells with TRIzol® reagent 
(Invitrogen) and cultured gastric muscle cells using ULTRASPECT
TM
 reagent from both antrum 
and fundus regions of the stomach and then treated with TURBO DNase (Ambion) . RNA from 
each preparation was reversely transcribed using the SuperScript™ II system containing 50 mM 
Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 0.5 mM 
deoxynucleoside triphosphates (dNTP), 2.5 μM random hexamers and 200 units of reverse 
transcriptase in a 20 μl reaction volume. The reactions were carried out at room temperature for 
10 min and at 42°C for 50 min, and terminated by heating at 70°C for 15 min. Three μl of the 
reversely transcribed cDNA was amplified in a final volume of 50 μl by PCR in standard 
conditions (2 mM MgCl2, 200 μM dNTP, 2.5 units Taq polymerase) with specific primers 
designed based on conserved sequences in human, rat and mouse cDNAs (Table 1).  PCR was 
performed for 30 cycles.  For each experiment, a parallel control without reverse transcriptase was 
processed.  The amplified PCR products were analyzed on 1.5% agarose gel containing 0.1 μg/ml 
ethidium bromide. 
2.2.6 Expression of telokin, CPI-17, α-tropomyosin, β-tropomyosin h-caldesmon, h1-
calponin, and smoothelin-A and smoothelin-B by Real Time PCR   
Real-time PCR was performed on cDNA samples synthesized from total RNA isolated 
from freshly dispersed smooth muscle cells and whole gastric tissue from antrum and fundus with 
TRIzol® reagent (Invitrogen) and from antrum and fundus cultured gastric muscle cells with the 
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StepOne™ Real-Time PCR System (Applied Biosystem, Foster city, CA) and the intercalating 
dye, SYBRgreen. Methods for total RNA isolation and cDNA synthesis were followed for the 
real-time PCR experiments. PCR conditions were optimized on the gradient thermal cycler on the 
StepOne™ Real-Time PCR System. For each cDNA sample, real-time PCR was conducted in a 
20 μl reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, 
Mississauga, ON). The following time and temperature profile was used for the real-time PCR 
reactions: 95 ˚C for 5 min; 50 cycles of a series consisting of 15 s at 94 ˚C, 30 s at 52 ˚C, 30 s at 
72 ˚C; and a final extension of 5 min at 72 ˚C. The optimal annealing temperatures were 
determined empirically for each primer set. The sequences of specific primers are listed in Table 
1. 
Real-time PCR reactions were performed in triplicate. Each primer set generated only one 
PCR product, and the identity and integrity of these products were confirmed by electrophoresis 
on 1.5% agarose gel containing 0.1 μg/ml ethidium bromide and sequencing of the individual 
bands. The fluorescent threshold value was calculated using the StepOne™ Real-Time PCR 
System software. The absence of peaks in water controls suggested a lack of primer-dimer 
formation.  
Quantification of gene expression.  Two general types of quantification strategies can be 
performed in quantitative RT-PCR (qRT-PCR). The levels of expressed genes may be measured 
by an absolute quantification or by a relative qRT-PCR. The absolute quantification approach 
relates the PCR signal to input copy number using a calibration curve
89
. 
Relative quantification relates the PCR signal of the target transcript in a treatment group 
to that of another sample such as an untreated control. Relative quantification of a target gene in 
relation to another gene (reference gene or housekeeping gene) can be calculated on the basis of 
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delta delta CT values (CT, called as well CP, is the cycle number at which the fluorescence 
generated within a reaction crosses the threshold. CT reflects the point during the reaction at 
which a sufficient number of amplicons has accumulated). There are several mathematical 
models to calculate the relative expression ratio (R), based on the comparison of the diverse cycle 
differences. Among them are the delta delta CT method 
90
 and the efficiency corrected calculation 
model
91
. In these models, the target-gene expression is normalized to the expression of one or 
more non-regulated housekeeping genes. The choice of an internal control to normalize the 
expression of the gene of interest is critical to the interpretation of experimental real-time PCR 
results. The housekeeping gene expression must not be influenced by the applied treatment
92
. 
Delta delta CT method  
ΔΔCT = (C
T, Tag 
− C
T, HKG
) 
Treatment 
− (C
T, Tag 
− C
T, HKG
) 
Control  
R = 2
−ΔΔCT 
 
Where, HKG is the housekeeping gene and Tag, the evaluated gene.  
Following the criteria for choosing the reference genes and delta delta method, in this study 
GAPDH was selected as reference gene. After normalization, the data for antrum were expressed 
as the fold-change in mRNA expression relative to that obtained for fundus.  
2.2.7  Transfection of dominant negative mutants and minigene constructs into cultured 
smooth muscle cells.  
Wild type telokin and phosphorylation-deficient telokin (S13A) were subcloned into the 
multiple cloning site (EcoR I) of the eukaryotic expression vector pcDNA3. Recombinant plasmid  
30 
Table 1. Real-time and RT-PCR primer sequences. Primers for amplification of different 
genes from smooth muscle tissue. AMPK; AMP kinase, MLCK; myosin light chain kinase, 
ZIPK; zipper interacting protein kinase, CPI-17; PKC potentiated inhibitor 17 kDa protein, 
PDE5; phosphodiesterase 5, MRP5; multi-drug resistance protein 5, Tm; tropomyosin, CaD; 
caldesmon, CaP; calponin, GAPDH; Glyceraldehyde 3-phosphate dehydrogenase, SMA/B; 
smooth muscle myosin (isoforms A and B), SM1/2; smooth muscle myosin (isoforms 1 and 2). 
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Primer set Forward 5’3’ Reverse 3’5’ Size (bp) 
AMPK TATGGTGGTCCACAGAGATTTGA TTTGCATTCATGTGTGCATCA 63 
MLCK GCCGAGCAGATGGATTTCC CTCTCCTCCTCAGACACAGTCTTG 71 
Rho Kinase 
CCAAACCTCTCTGGCATGTCTT TTAACATGGCATCTTCGACATTCT 
64 
ZIPK 
ATCCGCCACCCCAACAT TCAGCACCACATCTGTCTTGTTC 
64 
Telokin AACGGGCAATGCTGTGAGA GCCCTGAGATCATTGCCATAG 69 
CPI-17 GAGCAAGCTGCAGTCCCCGT GATCCACTTCTCCACGTCCA 116 
PDE5 CTATTCCCTGTTCCTTGTCTGTGA CAAAGAGGCGGCTGATAAGAA 65 
MRP5 GCAAGAGCCCTGCTGCGTCA CTGTGTGCAGGCGATGGGCA 151 
α-actin 
GTCACTTCCCTGCTCTGT GCTTTGGATAGGCATGACT 
97 
β-actin 
CCCTCCATCGTGCACCGCAA CTCGTCTCGTTTCTGCGCCGT 
100 
γ –actin ATCAGGCCCGCGACACTCGT 
GCCGCCAGTGTGCTCTAAAGGT 
70 
α-Tm 
CTGAAGCCGATGTAGCGTCTCTG ACGCTCCTGGGCACGATCCA 
75 
β-Tm 
CCTCCCTGAACCGCCGCATT TGACAAGACGCTCCTGCGCC 
67 
h-CaD 
CAGAAGGGAAGTCGGTAAATGAAA GGGCAGCTGTCTGAAGTTTATCTTCTT 
61 
h1-CaP 
GGTGAAGCCCCACGACAT CAAAGCCAGGAGGGTGGACTG 
86 
Smoothelin-A GCTGGTAAAAACCAAAAAGTCCTAA GCTTTTTGCCCATGATCATCA 107 
Smoothelin-B ATGAGGAGCGCAAGCTGATC GGCAGCCTCAATCTCCTGAGC 65 
GAPDH GCCTGGAGAAAGCTGCTAAGTATG CCTCGGATGCCTGCTTCA 60 
SMA/B 
CAGTCCATTCTCTGCACAGG TCATTCTTGACCGTCTTGGC 
197/218 
SM1/2 
TGAAGCAGAGGGACAAGAAG TTCTGGTAGGAACGAACGAG 
230/291 
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DNAs were transiently transfected into the muscle in primary culture using Effectene 
Transfection Reagent (QIAGEN) for 48 h.  Cells were co-transfected with 2 g of pcDNA3 
vector and 1 g of pGreen Lantern-1 DNA.  Transfection efficiency was monitored by the 
expression of the green fluorescent protein using FITC filters. Control cells were transfected with 
vector alone. Analysis by fluorescence microscopy showed that approximately 80% of the cells 
were transfected
30,93
. 
2.2.8    Immunokinase assay  
Activities of MLCK, AMPK, PKC, ZIPK, and Rho kinase were measured by an 
immunokinase assay as previously described
30,34,39,93-96
. Muscle cells were washed one time with 
PBS, and then were lysed with buffer containing 50 mM Tris-HCl (pH 7.5),150 mM NaCl, 0.1 % 
SDS, 0.5% sodium deoxycholate, 1% NP-40, 10 mM sodium pyrophosphate, and protease 
inhibitor cocktail (2 μl/ml, BD Biosciences). The homogenates were centrifuged at 10,000 rpm 
for 10 min at 4 C. The supernatant containing cytosolic protein was transferred to a fresh tube 
and 5 μl of the specific antibody was added to each tube and incubated for 2 h at 4 C.   
At the end of two hours, Protein A/G agarose was added to each tube and the mixture was 
reincubated at 4 C for overnight and washed 3 times with lysis buffer.  The pellets were re-
suspended in 50 μl of kinase buffer containing 100 mM Tris-HCl (pH 7.4), 1 M KCl, 50 mM 
MgCl2, 10 mM EDTA, and 1 mM DTT.  Twenty microliters of the immunoprecipitates were 
added to the reaction mixture containing 100 mM Tris-HCl (pH 7.4), 1 M KCl, 50 mM MgCl2, 1 
mM DTT, 1 mM ATP, and 10 μCi of [γ-32P] ATP (3,000 Ci/mol) along with 5 μg of myelin basic 
protein (for Rho kinase II, ZIPK an dPKC), or 1 µg purified recombinant MLCK (for AMPK), 
followed by incubation for 15 min at 37 C.  Phosphorylation of myelin basic protein or MLCK 
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was absorbed onto phosphocellulose disks, and free radioactivity was removed by washing 3 
times with 75 mM H3PO4.  The amount of radioactivity on the disks was measured by liquid 
scintillation. The results are expressed as counts per milligram protein per minute. 
2.2.9    Cyclic GMP-dependent protein kinase (PKG) assay 
 PKG activity was measured by the method of Jiang et al 
97
. One milliliter of cell 
suspension was incubated in HEPES medium with 8-Br-cGMP for 90 s at 31
0
C.  The reaction was 
stopped by rapid centrifugation, and the pellet was rinsed with a medium containing 50 mM Tris-
HCl (pH 7.4), 10 mM EDTA, 0.5 mM IBMX, 10 mM β-mercaptoethanol, and 100 mM NaCl and 
homogenized in 0.5 ml ice-cold medium.  The mixture was centrifuged at 48, 000 g for 15 min 
and the supernatant was used as a source of protein kinaase. PKG activity was measured in a 
volume of 60 µl containing 50 mM Tris, 10 mM MgCl2, 100 µM [
32
P]ATP, 50 µM synthetic 
heptapeptide histone H2B [Arg-Lys-Arg-Ser-Arg-Ala-Glu (RKRSRAE)], and 0.25 mg/ml of 
bovine serum albumin.  The assay was done in the presence or absence of 10 µM of cGMP and 1 
µM PKI (6-22 amide) and was initiated by the addition of 20 µl of cell supernatants (50 µg 
protein) to the reaction mixture.  PKG activity was calculated as pmoles/mg protein and expressed 
as the ratio of activity in the presence or absence of 10 µM cGMP (-cGMP/+cGMP). 
2.2.10  Western blot analysis    
Muscle cells were solubilized in Triton X-100-based lysis buffer plus protease and 
phosphatase inhibitors (100 μg/ml PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 30 mM sodium 
fluoride and 3 mM sodium vanadate). After centrifugation of the lysates at 20000 g for 10 min at 
4 °C, the protein concentrations of the supernatant were determined with a Dc protein assay kit 
from Bio-Rad. Equal amounts of proteins were fractionated by SDS/PAGE, and transferred on to 
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nitrocellulose membrane. Blots were blocked in 5% (w/v) non-fat dried milk/TBS-T [tris-buffered 
saline (pH 7.6) plus 0.1% Tween-20] for 1 h and then incubated overnight at 4 °C with various 
primary antibodies in TBS-T plus 1% (w/v) non-fat dried milk (Table 2). After incubation for 1 h 
with horseradish-peroxidase-conjugated corresponding secondary antibody (1:2000; 10 μg/ml, 
Pierce) in TBS-T plus 1% (w/v) non-fat dried milk, immunoreactive proteins were visualized 
using SuperSignal Femto maximum sensitivity substrate kit (Pierce). All washing steps were 
performed with TBS-T.  The protein bands were identified by enhanced chemiluminescence 
reagent.  
Quantification of protein bands obtained on western blot was done by densitometric 
analysis of the Details view of the Odyssey software using the median method for calculation of 
background.  The average intensity obtained for each band was normalized to that of β-actin for 
the same lane.  The band intensity of each treatment was then calculated as a percent value of 
normalized value of the control lane.  The percent value of the control was used for statistical 
analysis. 
2.2.11  Radioimmunoassay for cGMP. 
            Cyclic GMP levels were measured by radioimmunoassay, as previously described 
70
. 
Suspensions of smooth muscle cells (10
6
 cells/ml) were stimulated for 1 min with GSNO in the 
presence of 100 µM IBMX, and the reaction was terminated with 10% trichloroacetic acid. 
Samples were centrifuged, and the supernatant was extracted with diethyl ether and lyophilized. 
Samples were resuspended in Na-acetate buffer (pH 6.2) followed by acetylation with 
triethylamine-acetic anhydride for 10 min. cGMP was measured in duplicate using 100-µl 
aliquots, and the results are expressed as picomoles per milligram of protein. 
35 
Table 2. Primary antibodies. Primary antibodies and their catalogue number, company of 
production, product size and dilution ratio. 
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Antibody Catalog # 
Product 
size 
(kDa) 
Company name Dilution 
AMPKα1 (C-20) sc-19128 63 SANTA CRUZ  1/1000 
MYLK (L-18) sc-9452 210/135 SANTA CRUZ  1/1000 
Rock-2 (H-85)  sc-5561 160 SANTA CRUZ  1/1000 
ZIP-kinase (C-19) sc-8161 52 SANTA CRUZ  1/1000 
MYPT1 (N-15)  sc-17433 130 SANTA CRUZ  1/1000 
MRCL3/MRLC2/MYL9 (FL-172) sc-15370 20 SANTA CRUZ  1/1000 
Telokin sc-22226 17 SANTA CRUZ 1/1000 
CPI-17 (N-20)  sc-17561 17 SANTA CRUZ  1/1000 
PKC ε (17) sc-56944 82 SANTA CRUZ  1/1000 
PDE5 2395 100 CELL SIGNALING 1/1000 
MRP5 (C-17) sc-5780 185 SANTA CRUZ  1/1000 
PKG 7721301  PROMEGA 1/1000 
β-actin AC1978 42 SIGMA 1/5000 
Tropomyosin (FL-284)  sc-28543 35-45 SANTA CRUZ  1/1000 
Caldesmon (H-300):  sc-15374 90-150 SANTA CRUZ  1/1000 
Calponin 1 (CALP) sc-58707 33-36 SANTA CRUZ  1/1000 
37 
2.2.12 Phosphorylation of MLCK and AMPK 
Phosphorylation of MLCK and AMPK was determined from the amount of 
32
P 
incorporated into the enzyme after immunoprecipitation with MLCK or AMPK antibody 
respectively. A 10 ml suspension of smooth-muscle cells (4×10
6
 cells/ml) was prelabelled with 
0.5 mCi/ml of [
32
P]Pi for 3 h. Samples (1 ml) were treated with ACh in the presence or absence 
of various agents. The reaction was terminated with an equal volume of lysis buffer, containing 
1% (v/v) Triton X-100, 0.5% SDS, 10 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 100 µg/ml 
aprotinin, 10 mM sodium pyrophosphate, 50 mM NaF and 0.2 mM sodium vanadate. The cell 
lysates were separated from the insoluble material by centrifugation at 13000 g for 15 min at 4 
°C, precleared with 40 µl of Protein A–Sepharose and incubated with antibody to MLCK or 
AMPK for 2 h at 4 °C. After addition of Protein A–Sepharose (40 µl), the lysates were incubated 
for 1 h. The immunoprecipitates were washed five times with 1 ml of wash buffer containing 10 
mM Tris/HCl (pH 7.4), 150 mM NaCl and 0.5% Triton X-100, and extracted with SDS sample 
buffer. The samples were resolved by SDS/PAGE and 
32
P-labelled MLCK and AMPK were 
visualized by autoradiography, and the amount of radioactivity in the bands was counted. 
2.2.13  Assay for phosphodiesterase 5 (PDE5) activity 
PDE5 activity was measured in immunoprecipitates of PDE5 by the method of Wyatt et 
al. 
98
. PDE5 was immunoprecipitated from lysates of dispersed gastric smooth-muscle cells 
(3×10
6
 cells/ml) using an anti-PDE5 antibody, and the immunoprecipitates were washed in a 
solution of 50 mM Tris/HCl (pH 7.5), 200 mM NaCl and 5 mM EDTA. The immunoprecipitates 
were then incubated for 15 min at 30 °C in a reaction mixture containing 100 mM Mes (pH 7.5), 
10 mM EDTA, 0.1 M magnesium acetate, 0.9 mg/ml BSA, 20 µM cGMP and [
3
H] cGMP. The 
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samples were boiled for 3 min, chilled for 3 min and then incubated at 30 °C for 10 min in 20 
mM Tris/HCl (pH 7.5) containing 10 µl of C. atrox snake venom (10 µg/µl). The samples were 
added to DEAE-Sephacel A-25 columns and the radioactivity in the effluent was counted. The 
results were expressed as cpm/mg of protein.  
2.2.14   Immunoblot analysis of MLC20 and CPI-17 phosphoproteins. 
 Phosphorylation of MLC20 and CPI-17 was determined by
 
immunoblot analysis with 
phosphospecific antibodies as described
 
preciously 
30
. Muscle cells were treated with ACh or 
Ca
2+
 for 30 s or 10 min and solubilized on ice in a medium containing 20 mM Tris·HCl
 
(pH 8.0), 
1 mM DTT, 100 mM NaCl, 0.5% SDS, 0.75% deoxycholate,
 
1 mM PMSF, 10 µg/ml leupeptin, 
and 100 µg/ml aprotinin.
 
The lysate proteins were resolved by SDS-PAGE and transferred
 
onto 
polyvinylidene difluoride membranes. The membranes were
 
incubated for 12 h with 
phosphospecific antibodies to MLC20
 
(Ser
19
) or CPI-17 (Thr
38
) and then incubated
 
for 1 h with 
horseradish peroxidase-conjugated secondary antibodies.
 
The bands were identified by enhanced 
chemiluminescence.  Quantification of protein bands obtained on western blot was done by 
densitometric analysis as described above. 
2.2.15  Measurement of contraction and relaxation in dispersed smooth muscle cells 
Contraction in freshly dispersed gastric circular smooth muscle cells was determined by 
scanning micrometry
93
.   An aliquot (0.4 ml) of cells containing approximately 10
4
 cells/ml was 
treated with 100 μl of medium containing acetylcholine (ACh, 0.1 µM) for 30 s or 10 min  and the 
reaction was terminated with 1% acrolein at a final concentration of 0.1%.  Acrolein kills and 
fixes cells without affecting the cell length.   The resting cell length was determined in control 
experiments in which muscle cells were incubated with 100 l of 0.1% bovine serum albumin 
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without the ACh.    The mean lengths of 50 muscle cells treated with various agonists was 
measured by scanning micrometry and compared with the mean lengths of untreated cells. The 
contractile response was expressed as the percent decrease in mean cell length from control cell 
length.   
Relaxation was measured in intact muscle cells contracted with ACh (0.1 µM).  Muscle 
cells were treated for 1 minute with GSNO followed by ACh for 30 s or 10 min. The reaction was 
terminated with 1% acrolein. The length of 50 cells treated with acetylcholine was measured in 
sequential microscopic fields by scanning micrometry. Relaxation was expressed as percent 
increase in the length of cells contracted with ACh.  
2.2.16  Transfection of cultured smooth muscle cells with MRP5 siRNA 
 Confluent smooth muscle cells in the first passage on six-well plates were transiently 
transfected with the control vector or vector encoding MRP5 siRNA using Lipofectamine 2000 
according to the manufacturer's instructions (Invitrogen). Briefly, 2 µg of the vector in 125 µl 
Opti-MEM medium were mixed with 5 µl Lipofectamine 2000 in 125 µl Opti-MEM. The mixture 
was incubated at room temperature for 20 min and added to wells containing 1.5 ml DMEM with 
10% FBS for 1 day. The medium was then replaced with DMEM with 10% FBS plus antibiotics 
for 2 days. Cells were maintained for a final 24 h in DMEM without FBS before experiments 
were started.  
2.3.      Experimental approach 
1. We have used two approaches to determine the differences in smooth muscle 
contraction and relaxation signaling pathways in antrum versus fundus parts of the stomach.  In 
the first approach, freshly dispersed muscle cells were used to examine expression of various 
40 
proteins by western blot, enzyme activities by immuno kinase assay, protein phosphorylation, and 
smooth muscle contraction and relaxation in response to various reagents.  In the second 
approach, cultured muscle cells in the first passage were used for various molecular and 
biochemical studies.  The purity of cultured muscle cells was determined using markers for 
smooth muscle, interstial cells of Cajal, enteric neurons and endothelial cells. Use of cultured 
muscle cells is essential for mRNA expression by RT-PCR and real time PCR and for the 
expression of phosphorylation-deficient mutants of telokin cDNAs. 
2. Permeabilized muscle cells were used to preclude the effects of 8-Br-cGMP on 
mechanisms upstream of Ca
2+
 generation. 
3.  The concentrations of inhibitors used in the present study was based on the previous 
studies in smooth muscle cells and shown to be maximally effective in eliciting an inhibitory 
response
30,32-34,93
.  
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2.4       Statistical analysis 
The results were expressed as means  S.E. of n experiments and analyzed for statistical 
significance using Student‟s t-test for paired and unpaired values.  Each experiment was 
performed on cells obtained from different animals.  Differences among multiple groups were 
tested using ANOVA and checked for significance using Fisher‟s protected least significant 
difference test.  A statistical software program was used (GraphPad software, San Diego, CA).  A 
probability of p<0.05 was considered significant. 
CHAPTER 3  
DIFFERENTIAL EXPRESSION OF PROTEINS ASSOCIATED WITH THE 
CONTRACTILE FILAMENTS IN SMOOTH MUSCLE OF ANTRUM AND FUNDUS 
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Previous studies using esophagus and lower esophageal sphincter as models of phasic and 
tonic smooth muscle, respectively, have demonstrated that the expression of various contractile 
proteins is tissue specific and related to the function of the muscle 
99,100
.  Initially, studies were 
carried out to examine whether the expression of contractile proteins is different in muscle cells 
from antrum and fundus and correlates with the phasic and tonic phenotypes of the muscle, 
respectively.   
The mRNA expression levels of various contractile proteins were analyzed using specific 
primers by both RT-PCR and qRT-PCR in cultured muscle cells in the first passage.   As shown 
previously 
101
, the use of
 
confluent cultures of smooth muscle in the first passage ensured
 
the 
absence of neural, endothelial, or interstitial cell contaminants. 
 Specific primers were designed based on known sequences in rabbit, if available, or 
based on the conserved sequences in human, rat, and mouse cDNAs (Table 1).  In an initial 
evaluation, the accuracy of the designed primers was evaluated with agarose gels followed by 
sequencing of amplicons generated with the primers. Moreover, the formation of primer-dimers 
and the PCR efficiency of the primer sets were examined. Both the size and the sequence of all 
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real time RT-PCR amplicons were confirmed. Melt curve analyses showed single peaks for all 
samples. The PCR efficiencies were calculated from standard curves.  The values of the PCR 
efficiencies were higher than 90%, and the difference among them was not greater than 5%. 
These findings validated the design of primers and satisfied the requirements for use of the 2
-ΔΔCT 
quantification method, described previously in the Materials and Methods section. 
GAPDH expression was chosen to normalize the expression of the contractile proteins. 
The GAPDH amplicon was utilized to normalize and calculate the quantitative expression of 
various genes. Thus, a quantitative comparison between antrum and fundus tissue was 
calculated with the 2
-ΔΔCT 
method by normalizing the ΔCT counts to GAPDH expression.  
3.1        Actins 
 Expression of six different isoforms of actin with similar levels of acto-myosin ATPase 
activating property has been demonstrated in smooth muscle tissues. α- and γ-actin isoforms were 
found to be located primarily within the contractile apparatus, while β-actin is a highly conserved 
protein and shown to be the cytoskeletal actin isoform. The expression of α-actin is predominant 
in vascular smooth muscles, while expression of γ-actin is predominant in visceral smooth 
muscles. The expression of α, β and γ-actin isoforms were examined in antrum and fundus 
smooth muscle using isoform-specific primers (Table 1).  A PCR product with predicted size was 
detected for α-actin (97bp), γ- actin (70bp) or β-actin (100bp) in muscle cells from both antrum 
and fundus of rabbit stomach.   The differences in the expression levels were analyzed by qRT-
PCR.  The results showed that expression of α-actin was 11-fold (p<0.001, n=3) greater in muscle 
cells from fundus compared to muscle cells from antrum, whereas the expression of γ-actin was 
~3-fold (p<0.05, n=3) greater in muscle cells from antrum than fundus (Figure 1).  There was no 
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significant difference in the expression of β-actin between muscle cells from antrum and fundus 
(Figure 1).  
3.2         Tropomyosins 
  Expression two different isoforms of tropomyosin has been demonstrated in smooth 
muscle tissues 
102
.  Expression of both -tropomyosin and β-tropomyosin was measured in 
muscle cells of antrum and fundus.  The differences in the expression levels were analyzed by 
qRT-PCR.  The results showed that expression of α-tropomyosin was 5-fold greater, and β-
tropomyosin was 2-fold greater in muscle cells from antrum compared to fundus (Figure 2).   
Expression of tropomyosin was also examined in the two regions of the stomach by 
western blot analysis using an antibody that recognizes all the isoforms of tropomyosin. Results 
showed expression of 2 protein bands with ~45 kDa in the muscle cells from antrum, but only 
one band in muscle cells from fundus.  The molecular weight of the protein bands corresponds to 
the expected molecular weight of tropomyosin isoforms (35-45 kDa).  Comparing the densities of 
protein bands in the two regions revealed higher expression in muscle cells from antrum 
compared to fundus and this is consistent with higher expression of mRNA (Figure 2). 
3.3       Calponin and Caldesmon   
Calponin and caldesmon are thin filament associated proteins that were shown to regulate 
smooth muscle contraction.  They are differentially expressed in phasic (e.g., esophagus) versus 
tonic (e.g., lower esophageal sphincter) smooth muscles
99,100
.  Expression of h-caldesmon and h1-
calponin was analyzed by qRT-PCR in muscle cells from antrum and fundus.  The results showed 
that the expression of h1-calponin was 2-fold higher and h-caldesmon was 3-fold higher (p<0.05, 
n=3) in muscle cells from antrum compared to fundus.  Western blot analysis using antibody to 
h1-calponin or h-caldesmon demonstrated expression of h1-calponin (~35 kDa) and h-caldemon 
45 
(~100 kDa) in both antrum and fundus, and confirmed higher expression in muscle cells from 
antrum compared to fundus (Figure 3).  
3.4        Smoothelin 
 Expression two different isoforms of smoothelin has been demonstrated in smooth 
muscle tissues 
103
.  Expression of smoothelin-A isoform was found to be predominant in visceral 
smooth muscle cells, whereas expression of smoothelin-B isoform was found to be predominant 
in vascular smooth muscle.  Expression of smoothelin-A and -B isoforms was analyzed by qRT-
PCR in muscle cells from antrum and fundus.  The results showed that expression of smoothelin-
A was 4-fold (p<0.05, n=3) higher in muscle cells from antrum compared to fundus, whereas 
expression of smoothelin-B was 3-fold higher (p<0.05, n=3) in fundus compared to antrum 
(Figure 4).  
3.5        Myosin heavy chain 
 The smooth muscle myosin is a hexamer with a pair of heavy chains (220 kDa), a pair of 
20 kDa regulatory light chains or myosin light chains (MLC20) and a pair of 17 kDa essential 
light chains.  Myosin heavy chain is encoded by a single gene, but alternative splicing at two sites 
can create four different variants of this ~ 200 kDa polypeptide (SM1, SM2, SM-A and SM-B 
isoforms).  Expression of myosin heavy chain isoforms (SM1, SM2, SM-A and SM-B) was 
determined by RT-PCR.  PCR product of expected size was obtained using specific primers for 
SM1 (330 bp) and SM2 (291 bp) only in antrum, and the expression of SM1 appears to be greater 
than SM2 (Figure 5).  However, no detectable PCR product was obtained in fundus using same 
primers for SM1 and SM2.  Expression of SM-A and SM-B was also analyzed using specific 
primers for SM-A and SM-B.   Expression of both SM-A (197 bp) and SM-B (218 bp) isoforms 
was detected in fundus, but only SM-B was detected in antrum (Figures 5).  Expression of SM-B 
46 
appears to be higher in muscle cells from antrum compared to fundus.  The results are consistent 
with the higher expression of SM-B isoform in phasic muscle 
75
.   
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Figure 1. Expression of α-, β-, and γ- actin.  Total RNA isolated from cultured (first passage) 
gastric circular muscle cells from antrum and fundus using RNAqueous prep kits (Ambion, 
Austin, Tx) was reverse transcribed using 2 µg of total RNA using qScript cDNA prep kits 
(Quanta, Gaithersburg, MD).  The cDNA was amplified with specific primers for α-, β-, and γ-
actin. PCR products of expected size (97 bp, 100 bp, and 70 bp) were obtained with α-, β-, and γ-
actin primers, respectively.  The sequences of specific primers are listed in Table 1.  Quantitative 
real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of -actin, γ-
actin and β-actin.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction 
volume containing Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON).  Real-
time PCR reactions were performed in triplicate. Each primer set generated only one PCR 
product, and the identity and integrity of these products were confirmed by electrophoresis in 
agarose gel in the presence of ethidium bromide and sequencing of the individual bands (inset: 
representative PCR products of -actin, γ-actin and β-actin).   Standard curves for each amplicon 
were generated from a dilution series of cDNA and results were quantified and reported using the 
2
−ΔΔCT 
method based on GAPDH amplification.  GAPDH amplicon thresholds remained constant.   
Relative quantification of a target gene in relation to reference gene was calculated on the basis of 
delta delta CT values.  Results demonstrated that α-actin mRNA levels are higher, while γ-actin 
mRNA levels are lower in fundus compared to antrum. β-actin mRNA levels were similar in 
antrum and fundus.  Values represent the means SEM of 3 separate experiments.  *p<0.05 
versus fundus; **p<0.001 versus antrum 
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Figure 2. Expression of α- and β-tropomyosin.  Total RNA was isolated from cultured (first 
passage) muscle cells from antrum and fundus using RNAqueous prep kits (Ambion, Austin, Tx) 
was reverse transcribed using 2 µg of total RNA using qScript cDNA prep kits (Quanta, 
Gaithersburg, MD).  The cDNA was amplified with specific primers for α- or β-tropomyosin.  
PCR products of expected size (75bp, and 67bp,) were obtained with α-or β-tropomyosin primers 
respectively.  The sequences of specific primers are listed in Table 1.  Quantitative real-time 
polymerase chain reaction (qRT-PCR) was used to measure RNA levels of - or β-tropomyosin.  
For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume containing 
Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON).  Real-time PCR reactions 
were performed in triplicate. Each primer set generated only one PCR product, and the identity 
and integrity of these products were confirmed by electrophoresis in agarose gel in the presence 
of ethidium bromide and sequencing of the individual bands.   Standard curves for each amplicon 
were generated from a dilution series of cDNA and results were quantified and reported using the 
2
−ΔΔCT 
method based on GAPDH amplification.  GAPDH amplicon thresholds remained constant.   
Relative quantification of a target gene in relation to reference gene was calculated on the basis of 
delta delta CT values.  Results demonstrated that both α- and β-tropomyosin mRNA levels are 
higher in antrum compared to fundus.  Inset: Representative western blot results of tropomyosin 
expression.  Cell lysates containing equal amounts of total proteins were separated with SDS-
PAGE and expression of tropomyosin was analyzed using an antibody that recognizes all the 
isoforms of tropomyosin. Values represent the means SEM of 3 separate experiments.  *p<0.05 
versus fundus; **p<0.001 versus fundus. 
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Figure 2 
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Figure 3. Expression of h1-calponin and h-caldesmon.  Total RNA isolated from cultured (first 
passage) muscle cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  
The cDNA was amplified with specific primers for h1-clponin and h-caldesmon.  PCR products 
of expected size (86 bp and 61 bp) were obtained with h1-clponin and h-caldesmon primers 
respectively.  The sequences of specific primers are listed in Table 1.  Quantitative real-time 
polymerase chain reaction (qRT-PCR) was used to measure RNA levels of h1-clponin and h-
caldesmon.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume 
containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR reactions were performed 
in triplicate. Each primer set generated only one PCR product, and the identity and integrity of 
these products were confirmed by electrophoresis in agarose gel in the presence of ethidium 
bromide and sequencing of the individual bands.   Standard curves for each amplicon were 
generated from a dilution series of cDNA and results were quantified and reported using the 
2
−ΔΔCT 
method based on GAPDH amplification.  Relative quantification of a target gene in 
relation to reference gene was calculated on the basis of delta delta CT values.  Results 
demonstrated that both h1-calponin and h-caldesmon levels are higher in antrum compared to 
fundus.  Inset: Representative western blot results of calponin and caldesmon expression.  Cell 
lysates containing equal amounts of total proteins were separated with SDS-PAGE and 
expression of calponin or caldesmon was analyzed using selective antibody. Values represent the 
means SEM of 3 separate experiments.  *p<0.05 versus fundus. 
 
 
 
52 
Figure 3 
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Figure 4. Expression of smoothelin-A and smoothelin-B.  Total RNA isolated from cultured 
(first passage) muscle cells from antrum and fundus was reverse transcribed using 2 µg of total 
RNA.  The cDNA was amplified with specific primers for smoothelin-A and smoothelin-B.  PCR 
products of expected size (107 bp and 65 bp) were obtained with smoothelin-A and smoothelin-B 
primers, respectively.  The sequences of specific primers are listed in Table 1.  Quantitative real-
time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of smoothelin-A 
and smoothelin-B.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction 
volume containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR reactions were 
performed in triplicate. Each primer set generated only one PCR product, and the identity and 
integrity of these products were confirmed by electrophoresis by electrophoresis in agarose gel in 
the presence of ethidium bromide and sequencing of the individual bands.   Standard curves for 
each amplicon were generated from a dilution series of cDNA and results were quantified and 
reported using the 2
−ΔΔCT 
method based on GAPDH amplification.  Relative quantification of a 
target gene in relation to reference gene was calculated on the basis of delta delta CT values.  
Results demonstrated that expression of smoothelin-A is higher in antrum compared to fundus, 
whereas expression of smoothelin-B is higher in fundus compared to antrum.  Values represent 
the means SEM of 3 separate experiments.  **p<0.001 versus fundus for smoothelin-A, and 
versus antrum for smoothelin-B. 
 
 
 
 
54 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
Figure 5. Expression of myosin heavy chain isoforms (SM1/2 and SMA/B).  Total RNA 
isolated from cultured (first passage) gastric circular muscle cells from antrum and fundus was 
reverse transcribed using 2 µg of total RNA.  The cDNA was amplified with specific primers for 
SM1/2 or SM-A/SM-B. PCR products of expected size (330/291 bp and 197/218 bp) were 
obtained with SM1/2 or SM-A/SM-B primers respectively.  The sequences of specific primers are 
listed in Table 1.  Primers for SM1/2 generated two PCR products only in antrum, whereas 
primers for SM-A/SM-B generated one PCR product, corresponding to SM-B, in antrum and 2 
products corresponding to both SM-A and SM-B isoforms in fundus.   Results show 
representative PCR products of myosin heavy chain isoforms separated by electrophoresis in 
agarose gel in the presence of ethidium bromide and visualized by a ChemiImager Fluorescence 
system.   
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Figure 5 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4  
DIFFERENTIAL REGULATION OF MLCK ACTIVITY AND INITIAL MUSCLE 
CONTRACTION IN ANTRUM AND FUNDUS 
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In gastrointestinal smooth muscle, contraction-induced by Gq-coupled receptor agonists 
(e.g., acetylcholine) consists of a transient Ca
2+
-dependent phase and reflects sequential 
activation of PLC-β1, IP3-depedent Ca
2+
 release, Ca
2+
/CaM-dependent activation of MLCK and 
phosphorylation of Ser
19
 on MLC20, leading to interaction of actin and myosin and muscle 
contraction.  The levels of MLC20 phosphorylation and contraction are dependent on relative 
activities of MLCK and MLCP.  Ca
2+
/CaM complex stimulates MLCK activity and the affinity of 
MLCK for Ca
2+
/CaM is regulated by several mechanisms.  Recent studies have demonstrated that 
agonist-induced MLCK activity is regulated by AMPK in vascular smooth muscle.  Stimulation 
of AMPK activity was mediated by an upstream Ca
2+
/CaM-dependent protein kinase kinase-β 
(CaMKK-β), which phosphorylates AMPK at Thr172 and thus stimulates AMPK activity104.  We 
postulated that the rapid termination of contraction and MLCK activity by AMPK could 
contribute to the phasic phenotype of antrum.  
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4.1       Expression and activation of AMPK   
Expression of AMPK, by both qRT-PCR and western blot, and stimulation of AMPK 
activity in response to ACh (0.1µM) and depolarizing concentrations of KCl (20 mM) were 
determined in muscle cells from antrum and fundus.  AMPK1 mRNA was expressed in muscle 
cells from both antrum and fundus and the expression was 3-fold (p<0.001, n=3) greater in 
antrum compared to fundus (figure 6).  AMPK protein expression was examined in the two 
regions of the stomach by western blot using selective antibody to AMPKα1, the smooth muscle 
predominant isoform
105
. The results confirmed the expression of AMPKα1 of predicted size (63 
kDa) in the homogenates of smooth muscle cells of both antrum and fundus. Comparing the 
densities of protein bands in the two regions revealed a ~ 6-fold higher expression of AMPK in 
antrum compared to fundus (p<0.001, n=4) and this is consistent with the higher expression of 
AMPK mRNA in antrum compared to fundus (figure 6). 
Basal and agonist-stimulated AMPK activity was measured by immunokinase assay using 
recombinant MLCK as substrate.  Although, the expression levels are different, basal AMPK 
activity was not significantly different in antrum (7561860 cpm/mg protein) and fundus 
(5741602 cpm/mg protein).  Treatment of freshly dispersed muscle cells with ACh (0.1 µM) 
significantly increased AMPK activity in antrum (56734% increase; 443573672 cpm/mg 
protein above basal level), but not in fundus (Figure 7).  The results are consistent with higher 
expression of AMPK in antrum.   
Previous studies have shown that AMPK activity is stimulated by several upstream 
kinases including CaMKK-β, LKB1, and TAK1. CaMKK-β links AMPK activity with increase 
in intracellular Ca
2+
.  Freshly dispersed smooth muscle cells from both antrum and fundus 
were treated with ACh (0.1 M) in the presence or absence of STO609 (10 µM), a selective 
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inhibitor of CaMKKβ, BAPTA (10 µM), a selective Ca2+ chelator, or calmidazolium (10µM), 
a selective CaM antagonist.    
The increase in ACh-induced AMPK activity was blocked by pre-treatment of cells 
with STO609 (836% inhibition, p<0.001, n=4), BAPTA (7712% inhibition), or 
calmidazolum ( 898% inhibition) (Figures 7, 8, 9).  These results suggest that stimulation of 
AMPK activity in muscle cells from antrum is mediated by CaMKKβ in a Ca2+/calmodulin-
dependent manner.  
To examine whether stimulation of AMPK activity can be mediated by an increase 
intracellular Ca
2+
 without receptor activation, muscle cells were treated with depolarizing 
concentrations of KCl (20 mM ) for 30 s and AMPK activity was measured.  KCl significantly 
increased AMPK activity in antrum (51326% increase; 38801 3120 cpm/mg protein above 
basal level, but not in fundus (Figure 10). The extent of stimulation in antrum was similar to 
that induced by ACh.  KCl-induced AMPK activity was blocked by pre-treatment of cells with 
BAPTA (898% inhibition, p<0.001) or calmidazolium (826% inhibition) (Figures 10 and 
11).   
Further evidence for the involvement of phosphorylation in the stimulation of AMPK 
activity was obtained by measurement of AMPK phosphorylation in cells labeled with [
32
P]Pi 
followed by immunoblot with AMPK1 antibody in both antrum and fundus.  ACh induced 
significant phosphorylation of AMPK in muscle cell from antrum (2156402 cpm/mg protein), 
but had no effect in muscle cells from fundus (Figure 12).   
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Figure 6.  Expression of AMPK1.  Total RNA isolated from cultured (first passage) muscle 
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The cDNA was 
amplified with specific primers for AMPKα1.  The sequences of specific primers are listed in 
Table 1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA 
levels of AMPK1.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction 
volume containing TaqMan Gene Expression master Mix. Real-time PCR reactions were 
performed in triplicate. Each primer set generated only one PCR product (63 bp), and the identity 
and integrity of these products were confirmed by electrophoresis in agarose gel in the presence 
of ethidium bromide and sequencing of the individual bands.     Relative quantification of a target 
gene in relation to reference gene was calculated on the basis of delta delta CT values.  Results 
demonstrated that mRNA levels of AMPK1 are higher in antrum compared to fundus.  Inset: 
Representative western blot results of AMPK1 expression.  Cell lysates containing equal 
amounts of total proteins were separated with SDS-PAGE and expression of AMPK1 was 
analyzed using selective antibody for AMPK1.  Membranes were reblotted to measure β-actin. 
Protein bands visualized with enhanced chemiluminescence, images were quantified and 
densitometric values were calculated after normalization to β-actin density.  Results are expressed 
as fold increase over the expression of AMPK1 in fundus.   Values represent the means SEM 
of 3 separate experiments.  **p<0.001 versus fundus. 
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Figure 7.  Stimulation of AMPK activity by ACh and sensitivity to CAMKKβ antagonist.  
One milliliter of cell suspension (2 x 10
6
 cells/ml) freshly dispersed muscle cells from antrum and 
fundus were treated with ACh (0.1 µM) for 30 s in the presence or absence of STO609 (1 µM), a 
selective inhibitor of CaMKKβ.  The cells were homogenized in the lysis buffer and the protein 
content in the supernatants was measured.  AMPK was immunoprecipitated from lysates 
containing equal amounts of protein and the activity was measured in immunoprecipitates using 
purified recombinant MLCK as substrate and [
32
P]ATP.  The amount of radioactivity absorbed 
onto phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and 
the results are expressed as counts per milligram protein per minute.  ACh stimulated AMPK 
activity selectively in antrum and the stimulation was blocked by pretreatment of cells with 
STO609.  Values represent the means SEM of 4-5 separate experiments.  **p<0.001 versus 
basal activity in the absence of ACh. 
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Figure 8.  Ca
2+
-dependent stimulation of AMPK activity by ACh.  One milliliter of cell 
suspension (2 x 10
6
 cells/ml) freshly dispersed muscle cells from antrum and fundus were treated 
with ACh (0.1 µM) for 30 s in the presence or absence of BAPTA (10 µM), an intracellular Ca
2+
 
chelator.  The cells were homogenized in the lysis buffer and the protein content in the 
supernatants was measured.  AMPK was immunoprecipitated from lysates containing equal 
amounts of protein and the activity was measured in immunoprecipitates using purified 
recombinant MLCK as substrate and [
32
P]ATP.  The amount of radioactivity absorbed onto 
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  ACh stimulated AMPK activity 
selectively in antrum and the stimulation was blocked by pretreatment of cells with BAPTA.  
Values represent the means SEM of 4-5 separate experiments.  **p<0.001 significant increase 
above basal activity induced by ACh; ##p<0.05 significant inhibition of ACh-stimulated activity 
by BAPTA. 
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Figure 9.  Calmodulin-dependent stimulation of AMPK activity by ACh.  One milliliter of 
cell suspension (2 x 10
6
 cells/ml) freshly dispersed muscle cells from antrum and fundus were 
treated with ACh (0.1 µM) for 30 s in the presence or absence of calmidazolium (10 µM), a 
calmodulin antagonist.  The cells were homogenized in the lysis buffer and the protein content in 
the supernatants was measured.  AMPK was immunoprecipitated from lysates containing equal 
amounts of protein and the activity was measured in immunoprecipitates using purified 
recombinant MLCK as substrate and [
32
P]ATP.  The amount of radioactivity absorbed onto 
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  ACh stimulated AMPK activity 
selectively in antrum and the stimulation was blocked by pretreatment of cells with 
calmidazolium.  Values represent the means SEM of 4-5 separate experiments.  **p<0.001 
significant increase above basal activity induced by ACh; ##p<0.05 significant inhibition of 
ACh-stimulated activity by calmidazolium. 
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Figure 10.  Ca
2+
-dependent stimulation of AMPK activity by KCl.  One milliliter of cell 
suspension (2 x 10
6
 cells/ml) freshly dispersed muscle cells from antrum and fundus were treated 
with KCl (20 mM) for 30 s in the presence or absence of BAPTA (10 µM), an intracellular Ca
2+
 
chelator.  The cells were homogenized in the lysis buffer and the protein content in the 
supernatants was measured.  AMPK was immunoprecipitated from lysates containing equal 
amounts of protein and the activity was measured in immunoprecipitates using purified 
recombinant MLCK as substrate and [
32
P]ATP.  The amount of radioactivity absorbed onto 
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  KCl stimulated AMPK activity 
selectively in antrum and the stimulation was blocked by pretreatment of cells with BAPTA.  
Values represent the means SEM of 4-5 separate experiments.  **p<0.001 significant increase 
above basal activity induced by KCl; ##p<0.05 significant inhibition of KCl-stimulated activity 
by BAPTA. 
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Figure 11.  Calmodulin-dependent stimulation of AMPK activity by KCl.  One milliliter of 
cell suspension (2 x 10
6
 cells/ml) freshly dispersed muscle cells from antrum and fundus were 
treated with KCl (20 mM) for 30 s in the presence or absence of calmidazolium (10 µM), a 
calmodulin antagonist.  The cells were homogenized in the lysis buffer and the protein content in 
the supernatants was measured.  AMPK was immunoprecipitated from lysates containing equal 
amounts of protein and the activity was measured in immunoprecipitates using purified 
recombinant MLCK as substrate and [
32
P]ATP.  The amount of radioactivity absorbed onto 
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  KCl stimulated AMPK activity 
selectively in antrum and the stimulation was blocked by pretreatment of cells with 
calmidazolium.  Values represent the means SEM of 4-5 separate experiments.  **p<0.001 
significant increase above basal activity induced by KCl; ##p<0.05 significant inhibition of KCl-
stimulated activity by calmidazolium. 
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Figure 12.  Phosphorylation of AMPK by ACh.  Ten milliliter of cell suspension (2 x 10
6
 
cells/ml) freshly dispersed muscle cells from antrum and fundus were labeled with 
32
P and the 
cells were incubated with ACh for 30s.  AMPK was immunoprecipitated from the cell lysates 
containing equal amount of protein, extracted with Laemmeli buffer and separated by 
electrophoresis on SDS-PAGE.  Phosphorylated AMPK was visualized by autoradiography, and 
the amount of radioactivity in the protein band was measured. The results are expressed as counts 
per milligram protein per minute.  Values represent the means SEM of 3 separate experiments.  
**p<0.001 significant increase in phosphorylation above basal level induced by ACh. 
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4.2       Feedback inhibition of MLCK activity   
MLCK is the main enzyme responsible for MLC20 phosphorylation, and thus smooth 
muscle contraction.    Expression of MLCK, by both qRT-PCR and western blot, and stimulation 
of MLCK activity in response to ACh (0.1µM) were determined in muscle cells from antrum and 
fundus.  MLCK mRNA was expressed in muscle cells from both antrum and fundus, and the 
expression was 3-fold higher (p<0.05 n=3) in antrum compared to fundus (Figure 13).  MLCK 
protein expression was examined in the two regions of the stomach by western blot using 
selective antibody to MLCK.  Results confirmed the expression of MLCK of predicted size (135 
kDa) in the homogenates of smooth muscle cells from both antrum and fundus (Figure 13). 
Comparing the densities of protein bands in the two regions revealed that there was nearly 2-fold 
higher expression MLCK in muscle cells from antrum compared to fundus.   
Basal and agonist-stimulated MLCK activity was measured by immunokinase assay using 
MLC20 as substrate.  Basal MLCK activity was not significantly different in antrum (1249116 
cpm/mg protein) and fundus (1464236 cpm/mg protein).  Treatment of freshly dispersed muscle 
cells with ACh (0.1 µM) significantly increased MLCK activity in antrum (94356% increase, 
127211038 cpm/mg protein above basal level, p<0.001, n=4) and fundus (82156% increase; 
120451306 cpm/mg protein above basal level, p<0.001, n=4) (Figure 14).   
Despite higher expression of MLCK in antrum, agonist-stimulated MLCK activity in antrum and 
fundus was similar. This raised the possibility that MLCK activity might be negatively regulated 
in antrum via a feedback mechanism involving AMPK.  To examine this notion, ACh-stimulated 
MLCK activity was measured in the presence of STO609, an inhibitor of CaMKK/AMPK 
pathway.  ACh-stimulated MLCK activity was significantly augmented (19435% increase above 
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ACh treatment alone, p<0.001, n=4) in the presence of STO609 in muscle cells from antrum.  
STO609 had no effect on ACh-stimulated MLCK activity in muscle cells from fundus (Figure 
14).  These results suggest that MLCK activity is negatively regulated in a feedback mechanism 
via CaMKKβ/AMPK pathway in antrum, but not in fundus.  The results are consistent with the 
higher expression and activation of AMPK in antrum. 
   Further evidence for the involvement of AMPK in the regulation of MLCK activity was 
obtained by measurement of MLCK phosphorylation in cells labeled with [
32
P]Pi followed by 
immunoblot with MLCK antibody in both antrum and fundus.  ACh induced significant 
phosphorylation of MLCK in muscle cell from antrum (3562564 cpm/mg protein), but had no 
effect in muscle cells from fundus (Fig 15).   
4.3       Regulation of initial muscle contraction by CaMKKβ/AMPK pathway 
The inhibition of MLCK activity by AMPK in antrum muscle could contribute to its 
phasic phenotype.  To examine the involvement of CaMKK/AMPK pathway in the regulation of 
muscle contraction, muscle cells from antrum and fundus were treated with different 
concentrations of ACh for 30 s in the presence or absence of STO609 (10µM) and the decrease in  
cell length was measured by scanning micrometry. Previous studies in gastrointestinal smooth 
muscle have demonstrated that the contractile response at 30 s reflects Ca
2+
/CaM-depedent 
activation of MLCK.  Control cell length in muscle cells from antrum and fundus are similar 
(953 µm in antrum and 1025 µm in fundus).  ACh caused contraction that was concentration-
dependent with an EC50 of 21 nM in antrum and 32 nM in fundus and the maximal response to 
0.1 µM of ACh was similar in antrum and fundus (272% decrease in cell length in antrum and 
283% decrease in cell length in fundus) (Figure 16).  However, pretreatment of cells with 
STO609 significantly augmented ACh-induced contraction in muscle cells from antrum and 
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shifted the concentration-response curve to the left (EC50 0.090.06 nM).  In contrast, STO609 
had no effect on contraction in fundus.  The results are consistent with the selective augmentation 
of MLCK activity by STO609 in muscle cells from antrum, and further confirm the inhibitory 
regulation of MLCK activity by AMPK. 
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Figure 13.  Expression of MLCK.  Total RNA isolated from cultured (first passage) muscle 
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The cDNA was 
amplified with specific primers for MLCK.  The sequences of specific primers are listed in Table 
1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels 
of MLCK.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume 
containing TaqMan GeneExpression Master Mix.  Real-time PCR reactions were performed in 
triplicate. Each primer set generated only one PCR product (71 bp), and the identity and integrity 
of these products were confirmed by electrophoresis in agarose gel in the presence of ethidium 
bromide and sequencing of the individual bands.   Relative quantification of a target gene in 
relation to reference gene was calculated on the basis of delta delta CT values.  Results 
demonstrated that mRNA levels of MLCK are higher in antrum compared to fundus.  Inset: 
Representative western blot results of MLCK expression.  Cell lysates containing equal amounts 
of total proteins were separated with SDS-PAGE and expression of MLCK was analyzed using 
selective antibody for MLCK.  Membranes were reblotted to measure β-actin. Protein bands were 
visualized with enhanced chemiluminescence, images were quantified and densitometric values 
were calculated after normalization to β-actin density.  Results are expressed as fold increase over 
the expression of MLCK in fundus.   Values represent the means SEM of 3 separate 
experiments.  *p<0.05 versus fundus. 
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Figure 14.  Stimulation of MLCK activity by ACh and sensitivity to CAMKKβ antagonist. 
One milliliter of cell suspension (2 x 10
6
 cells/ml) freshly dispersed muscle cells from antrum and 
fundus were treated with ACh (0.1 µM) for 30 s in the presence or absence of STO609 (1 µM), a 
selective inhibitor of CaMKKβ/AMPK pathway.  The cells were homogenized in the lysis buffer 
and the protein content in the supernatants was measured.  MLCK was immunoprecipitated from 
lysates containing equal amount of protein and the activity was measured in immunoprecipitates 
using MLC20 as substrate and [
32
P] ATP.  The amount of radioactivity absorbed onto 
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  ACh stimulated MLCK activity 
in antrum and fundus.  Stimulation of MLCK activity was augmented in antrum by pretreatment 
of cells with STO609, suggesting feedback inhibition of MLCK activity selectively in antrum.  
Values represent the means SEM of 4-5 separate experiments.  **p<0.001 significant increase in 
activity above basal level induced by ACh; ##p<0.05 significant augmentation of ACh-stimulated 
MLCK activity by STO609. 
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Figure 15.  Phosphorylation of MLCK by ACh.  Ten milliliter of cell suspension (2 x 10
6
 
cells/ml) of freshly dispersed muscle cells from antrum and fundus were labeled with 
32
P and the 
cells were incubated with ACh for 30s.  MLCK was immunoprecipitated from the cell lysates 
containing equal amount of protein, extracted with Laemmeli buffer and separated by 
electrophoresis on SDS-PAGE.  Phosphorylated MLCK was visualized by autoradiography, and 
the amount of radioactivity in the protein band was measured. The results are expressed as counts 
per milligram protein per minute.  Values represent the means SEM of 3 separate experiments.  
**p<0.001 significant increase in phosphorylation above basal level induced by ACh. 
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Figure 16.  Effect of STO609 on ACh-induced muscle contraction.  Contraction of dispersed 
muscle cells from antrum and fundus was measured by scanning micrometry in response to 
different concentrations of ACh in the presence or absence of STO609 (10 µM).  Cells were 
treated with ACh for 30s and pretreated with STO609 for 10 min.  Contraction was expressed as 
percent decrease in cell length from control cell length: control length of muscle cells from 
antrum 953 µm; control length of muscle cells from fundus 1025 µm.  ACh caused contraction 
that was concentration-dependent in both antrum and fundus and the maximal response to 0.1 µM 
of ACh was similar in antrum and fundus (272% decrease in cell length in antrum and 283% 
decrease in cell length in fundus). STO609 significantly augmented ACh-induced contraction in 
muscle cells from antrum, but had no effect on contraction in fundus. Values represent the means 
SEM of 4 separate experiments.  *p<0.05 significant increase in contraction by STO609. 
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CHPATER 5 
DIFFERENTIAL REGULATION OF MLCP ACTIVITY AND SUSTAINED MUSCLE 
CONTRACTION IN ANTRUM AND FUNDUS 
85 
 
 
 
 
In smooth muscle, inhibition of MLCP activity and sustained MLC20 phosphorylation by 
contractile agonists reflect activation of RhoA via G13 and/or Gq.  The pathways that lead to 
inhibition of MLCP involve phosphorylation of the regulatory subunit of MLCP (MYPT1) via 
Rho kinase and phosphorylation of CPI-17, an endogenous inhibitor of MLCP, via PKC.  A role 
for ZIPK has also been suggested in the phosphorylation of MYPT1.  We postulated that the 
higher expression and/or activation of Rho kinase/MYPT1 and PKC/CPI-17 pathways leading to 
sustained MLC20 phosphorylaiton could contribute to the tonic phenotype of fundus.     
5.1         Rho kinase expression and activity 
  Expression of Rho kinase, by both qRT-PCR and western blot, and stimulation of Rho 
kinase activity in response to ACh (0.1µM) were determined in muscle cells from antrum and 
fundus.  Rho kinase mRNA was expressed in both antrum and fundus and the expression was 3-
fold (p<0.05, n=3) greater in fundus compared to antrum (Figure 17).  Rho kinase protein 
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expression was examined in the two regions of the stomach by western blot using selective 
antibody to Rho kinase II, the smooth muscle predominant isoform 
32
.  Results confirmed the 
expression of Rho kinase of predicted size (150 kDa) in the homogenates of smooth muscle cells 
from both antrum and fundus.  Comparing the densities of protein bands in the two regions 
revealed higher expression of Rho kinase in fundus compared to antrum (p<0.001, n=4) and this 
is consistent with higher expression of Rho kinase mRNA in fundus compared to antrum (Figure 
17). 
To determine whether Rho kinase activity level correlates well with its expression profile 
and thus with the contractile phenotypes in the fundus vs. antrum, freshly dispersed smooth 
muscle cells from both parts of the stomach were treated with 0.1µM ACh, a Gαq/13-coupled 
receptor agonist, for 10 min, and basal and agonist-stimulated Rho kinase activity was measured 
by immunokinase assay using recombinant myelin basic protein as substrate.  Although, the 
expression levels are different, basal Rho kinase activity was not significantly different in antrum 
(3242367 cpm/mg protein) and fundus (4364503 cpm/mg protein).  Treatment of freshly 
dispersed muscle cells with ACh significantly increased Rho kinase activity in antrum (23815% 
increase; 7730821 cpm/mg protein above basal level, p<0.001, n=5) and fundus (36221% 
increase; 158201423 cpm/mg protein above basal level, p<0.001, n=5) (Figure 18).  Consistent 
with the greater expression of Rho kinase in fundus, agonist-stimulated Rho kinase activity was 
significantly higher in fundus compared to antrum.  Y27632, a selective blocker of Rho kinase, 
significantly inhibited stimulation of Rho kinase activity in both antrum (904% inhibition, 
p<0.001, n=5) fundus (965 % inhibition, p<0.001, n=5) (Figure 18). 
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Figure 17.  Expression of Rho kinase II. Total RNA isolated from cultured (first passage) 
muscle cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The 
cDNA was amplified with specific primers for Rho kinase II.  The sequences of specific primers 
are listed in Table 1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was used to 
measure RNA levels of Rho kinase II.  For each cDNA sample, real-time PCR was conducted in 
a 20 μl reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR 
reactions were performed in triplicate. Each primer set generated only one PCR product (64 bp), 
and the identity and integrity of these products were confirmed by electrophoresis in agarose gel 
in the presence of ethidium bromide and sequencing of the individual bands. Standard curves for 
each amplicon were generated from a dilution series of cDNA and results were quantified and 
reported using the 2
−ΔΔCT 
method based on GAPDH amplification.  Relative quantification of a 
target gene in relation to reference gene was calculated on the basis of delta delta CT values.  
Results demonstrated that mRNA levels of Rho kinase II are higher in fundus compared to 
antrum.  Inset: Representative western blot results of Rho kinaseII expression.  Cell lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of 
Rho kinase II was analyzed using selective antibody for Rho kinase II.  Membranes were 
reblotted to measure β-actin. Protein bands visualized with enhanced chemiluminescence, images 
were quantified and densitometric values were calculated after normalization to β-actin density.  
Results are expressed as fold increase over the expression of Rho kinase II in antrum.   Values 
represent the means SEM of 3 separate experiments.  **p<0.001 versus antrum. 
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Figure 18.  Stimulation of Rho kinase activity by ACh. One milliliter of cell suspension (2x 
10
6
 cells/ml) of freshly dispersed muscle cells from antrum and fundus was treated with ACh (0.1 
µM) for 10 min in the presence or absence of Y27632 (1 µM), a selective inhibitor of Rho kinase.  
The cells were homogenized in the lysis buffer and the protein content in the supernatants was 
measured.  Rho kinase II was immunoprecipitated from lysates containing equal amount of 
protein and the activity was measured in immunoprecipitates using purified recombinant myelin 
basic protein as substrate and [
32
P]ATP.  The amount of radioactivity absorbed onto 
phosphocellulose disks reflecting kinase activity was by measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  ACh stimulated Rho kinase II 
activity in antrum and fundus and the stimulation was higher in fundus compared to antrum. 
Y27632 blocked stimulation of Rho kinase activity in both antrum and fundus.  Values represent 
the means SEM of 5-6 separate experiments.  **p<0.001 significant increase in activity above 
basal level induced by ACh; ##p<0.05 significant increase in activity in fundus versus increase in 
antrum  
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5.2         ZIPK expression and activity 
  Zipper interacting protein kinase (ZIPK) was also shown to inhibit MLCP activity via 
phosphorylation of MYPT1 at Thr
696
.  So, it is of interest to reveal any differential expression and 
activity of this kinase in antrum versus fundus.  Expression of ZIPK, by both qRT-PCR and 
western blot, and stimulation of ZIPK activity in response to ACh (0.1µM) were determined in 
muscle cells from antrum and fundus.  ZIPK mRNA was expressed in both antrum and fundus, 
and the expression was not significantly different between fundus and antrum (Figure 19).  ZIPK 
kinase protein expression was examined in the two regions of the stomach by western blot 
analysis using selective antibody to ZIPK.  Results confirmed the expression of ZIPK of expected 
size (52 kDa) in the homogenates of smooth muscle cells from both antrum and fundus.  
Comparing the densities of protein bands in the two regions revealed no significant difference of 
ZIPK expression between fundus and antrum (figure 19). 
ZIPK activity was measured by immunokinase assay using recombinant myelin basic 
protein as substrate.  Basal ZIPK activity was not significantly different in antrum (3106308    
cpm/mg protein) and fundus (4107372 cpm/mg protein).  Treatment of freshly dispersed muscle 
cells with ACh (0.1 µM) significantly increased ZIPK activity in antrum (20511% increase; 
6375438 cpm/mg protein above basal level, p<0.001, n=5) and fundus (4418% increase; 
222571980 cpm/mg protein above basal level, p0.001, n=5) (Figure 20).   Consistent with the 
greater expression and activation of Rho kinase in fundus, ACh-stimulated ZIPK activity was 
significantly higher in fundus compared to antrum. ACh stimulated ZIPK activity was blocked by 
pretreatment of cells with Y27632 (1 µM), a selective Rho kinase inhibitor, in antrum (845% 
inhibition) and fundus (955% inhibition) (Figure 20).  These results suggest that ZIPK is a 
downstream target of Rho kinase. 
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Figure 19.  Expression of zipper interacting protein kinase.  Total RNA isolated from cultured 
(first passage) muscle cells from antrum and fundus was reverse transcribed using 2 µg of total 
RNA.  The cDNA was amplified with specific primers for ZIPK.  The sequences of specific 
primers are listed in Table 1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was 
used to measure RNA levels of ZIPK.  For each cDNA sample, real-time PCR was conducted in a 
20 μl reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR 
reactions were performed in triplicate. Each primer set generated only one PCR product (64 bp), 
and the identity and integrity of these products were confirmed by electrophoresis in agarose gel 
in the presence of ethidium bromide and sequencing of the individual bands.   Standard curves for 
each amplicon were generated from a dilution series of cDNA and results were quantified and 
reported using the 2
−ΔΔCT
 method based on GAPDH amplification.  Relative quantification of a 
target gene in relation to reference gene was calculated on the basis of delta delta CT values.  
Results demonstrated that mRNA levels of ZIPK are not significantly different between fundus 
and antrum.  Inset: Representative western blot results of ZIPK expression.  Cell lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of 
ZIPK was analyzed using selective antibody for ZIPK.  Membranes were reblotted to measure β-
actin. Protein bands were visualized with enhanced chemiluminescence, images were quantified 
and densitometric values were calculated after normalization to β-actin density.  Results are 
expressed as fold increase over the expression of ZIPK in antrum.   Values represent the means 
SEM of 3 separate experiments.  
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Figure 20.  Stimulation of ZIPK by ACh and sensitivity to the Rho kinase inhibitor, Y27632.  
One milliliter of cell suspension (2x 10
6
 cells/ml) of freshly dispersed muscle cells from antrum 
and fundus was treated with ACh (0.1 µM) for 10 min in the presence or absence of Y27632 (1 
µM), a selective inhibitor of Rho kinase.  The cells were homogenized in the lysis buffer and the 
protein content in the supernatants was measured.  ZIPK was immunoprecipitated from lysates 
containing equal amount of protein and the activity was measured in immunoprecipitates using 
purified recombinant myelin basic protein as substrate and [
32
P]ATP.  The amount of 
radioactivity absorbed onto phosphocellulose disks reflecting kinase activity was measured by 
liquid scintillation and the results are expressed as counts per milligram protein per minute.  ACh 
stimulated ZIPK activity in antrum and fundus and the stimulation was higher in fundus 
compared to antrum. Y27632 blocked stimulation of ZIPK activity in both antrum and fundus.  
Values represent the means SEM of 5-6 separate experiments.  **p<0.001 significant increase in 
activity above basal level induced by ACh; ##p<0.05 significant increase in activity in fundus 
versus increase in antrum  
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5.3       Sustained contraction   
To examine the involvement of Rho kinase/ZIPK pathway in the regulation of muscle 
contraction, muscle cells from antrum and fundus were treated with different concentrations of 
ACh and contractile response at 10 min was measured by scanning micrometry. Previous studies 
in gastrointestinal smooth muscle have demonstrated that the contractile response at 10 min 
reflects activation of Rho kinase- and PKC-dependent inhibition of MLCP.  Treatment of cells 
with ACh for 10 min caused contraction that was concentration-dependent with an EC50 of 1.1  
0.3 nM in antrum and 0.70.03 nM in fundus.  The maximal response was significantly greater in 
muscle cells from fundus (262 % decrease in cell length) compared to muscle cells from antrum 
(182% decrease in cell length) (figure 21).   
5.4       CPI-17 Expression   
As described earlier, sustained MLC20 phosphorylation and muscle contraction are 
mediated by inhibition of MLCP via Rho kinase/MTPT1 and PKC/CPI-17 pathways.  Expression 
of CPI-17, by both qRT-PCR and western blot was determined in muscle cells from antrum and 
fundus.  CPI-17 mRNA was expressed in antrum and fundus and the expression was nearly 4-fold 
higher in fundus compared to antrum (figure 22).  CPI-17 protein expression was examined in the 
two regions of the stomach by western blot using selective antibody to CPI-17. Results confirmed 
the expression of CPI-17 of expected size (17 kDa) in the homogenates of smooth muscle cells 
from both antrum and fundus (Figure 22).  Comparing the densities of protein bands in the two 
regions revealed 4-fold (p<0.05) higher expression of CPI-17 in fundus compared to antrum and 
this is consistent with higher expression of CPI-17 mRNA in fundus compared to antrum. 
5.5       PMA-stimulated PKC activity and smooth muscle contraction    
97 
Since contractile agonists stimulate both Rho kinase and PKC activities, the singular 
contribution of PKC/CPI-17 pathway in mediating MLCP inhibition and sustained contraction 
was examined using phorbol 12-myristate 13-acetate (PMA), a selective activator of PKC.  
Treatment of cells with PMA caused contraction that was concentration-dependent with an EC50 
of 355 nM in antrum and 32 nM in fundus.  The maximal contractile response was 
significantly greater in muscle cells from fundus (292% decrease in cell length) compared to 
muscle cells from antrum (173% decrease in cell length) (figure 23A).  However, stimulation of 
PKC activity in response to PMA was similar in antrum (3245504 cpm/mg protein above the 
basal level of 523102 cpm/mg protein) and fundus (3612302 cpm/mg protein above the basal 
level 675129 cpm/mg protein) (Figure 23B).  These results suggest that greater contraction in 
fundus is not due difference in the PKC activity, but probably due to higher expression of CPI-17 
and CPI-17-mediated inhibition of MLCP activity.  
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Figure 21.  ACh-induced sustained muscle contraction.   Contraction of dispersed muscle cells 
from antrum and fundus in response to different concentrations of ACh was measured by 
scanning micrometry.  Cells were treated with ACh (0.1 µM) for 10 min and cntraction was 
expressed as percent decrease in cell length from control cell length: control length of muscle 
cells from antrum 953 µm; control length of muscle cells from fundus 1025 µm.  ACh caused 
contraction that was concentration-dependent in both antrum and fundus and the contraction was 
greater in fundus compared to antrum.  The  maximal response to 0.1 µM ACh was significantly 
greater in muscle cells from fundus (262 % decrease in cell length) compared to muscle cells 
from antrum (182% decrease in cell length).  Values represent the means SEM of 4 separate 
experiments.  *p<0.05 significant increase in contraction in fundus versus contraction in antrum. 
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Figure 22.  Expression of CPI-17.   Total RNA isolated from cultured (first passage) muscle 
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The cDNA was 
amplified with specific primers for CPI-17.  The sequences of specific primers are listed in Table 
1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels 
of CPI-17.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume 
containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR reactions were performed 
in triplicate. Each primer set generated only one PCR product (116 bp), and the identity and 
integrity of these products were confirmed by electrophoresis in agarose gel in the presence of 
ethidium bromide and sequencing of the individual bands.   Standard curves for each amplicon 
were generated from a dilution series of cDNA and results were quantified and reported using the 
2
−ΔΔCT
 method based on GAPDH amplification.  Relative quantification of a target gene in 
relation to reference gene was calculated on the basis of delta delta CT values.  Results 
demonstrated that mRNA levels of CPI-17 are significantly higher in fundus compared to antrum.  
Inset: Representative western blot results of CPI-17 expression.  Cell lysates containing equal 
amounts of total proteins were separated with SDS-PAGE and expression of CPI-17 was 
analyzed using selective antibody for CPI-17.  Membranes were reblotted to measure β-actin. 
Protein bands visualized with enhanced chemiluminescence, images were quantified and 
densitometric values were calculated after normalization to β-actin density.  Results are expressed 
as fold increase over the expression of CPI-17 in antrum.   Values represent the means SEM of 3 
separate experiments. **p<0.05 versus antrum. 
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Figure 23.  PMA-induced sustained muscle contraction and PKC activity.  A.  Contraction of 
dispersed muscle cells from antrum and fundus in response to different concentrations of phorbol 
12-myristate 13-acetate (PMA) was measured by scanning micrometry.  Contraction was 
expressed as percent decrease in cell length from control cell length: control length of muscle 
cells from antrum 953 µm; control length of muscle cells from fundus 1025 µm.  PMA caused 
contraction that was concentration-dependent in both antrum and fundus and the contraction was 
greater in fundus compared to antrum.  The maximal response to 1 µM PMA was significantly 
greater in muscle cells from fundus (292 % decrease in cell length) compared to muscle cells 
from antrum (172% decrease in cell length).  Values represent the means SEM of 4 separate 
experiments.  *p<0.05 significant increase in contraction in fundus versus contraction in antrum.  
B.  One milliliter of cell suspension (2x 10
6
 cells/ml) of freshly dispersed muscle cells from 
antrum and fundus was treated with PMA (1 µM) for 10 min.  The cells were homogenized in the 
lysis buffer and the protein content in the supernatants was measured.  PKC was 
immunoprecipitated from lysates containing equal amount of protein with a PKC antibody and 
the activity was measured in immunoprecipitates using purified recombinant myelin basic protein 
as substrate and [
32
P]ATP.  The amount of radioactivity absorbed onto phosphocellulose disks 
reflecting kinase activity was by measured by liquid scintillation and the results are expressed as 
counts per milligram protein per minute above basal levels of 523102 cpm/mg protein in antrum 
and 675129 cpm/mg protein in fundus.  PMA stimulated PKC activity was similar in antrum 
and fundus.  Values represent the means SEM of 4 separate experiments.   
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CHAPTER 6 
DIFFERENTIAL REGULATION OF MLCP ACTIVITY AND MUSCLE RELAXATION 
IN ANTRUM AND FUNDUS 
104 
 
 
 
In gastrointestinal smooth muscle two endogenous proteins regulate MLCP activity: a 17 
kDa inhibitor (CPI-17) and a 17 kDa activator, telokin, also known as kinase-related protein.  
Telokin is a smooth muscle specific protein and is identical to the C-terminus of MLCK 
downstream from the kinase and calmodulin binding domains.  We postulated that the higher 
expression of telokin, and activation MLCP leading to MLC20 dephosphorylation could 
contribute to rapid relaxation and phasic phenotype of antrum.     
6.1       Telokin Expression   
Expression of telokin by both qRT-PCR and western blot was determined in muscle cells 
from antrum and fundus.  Telokin mRNA was expressed in both antrum and fundus and the 
expression was 6-fold higher in antrum compared to fundus (figure 24).  Telokin protein 
expression was examined in the two regions of the stomach by western blot using selective 
antibody to telokin.  Results confirmed the expression of telokin of expected size (17 kDa) in the 
homogenates of smooth muscle cells from both antrum and fundus (Figure 24). Comparing the 
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densities of protein bands in the two regions revealed 5-fold higher expression of telokin in 
antrum compared to fundus and this is consistent with higher expression of telokin mRNA in 
antrum compared to fundus. 
6.2       8-Br-cGMP-stimulated PKG activity and smooth muscle relaxation   
Since the relaxant effect of cGMP/PKG pathway on agonist-mediated (e.g., ACh) 
contraction involves both inhibition of intracellular Ca
2+
 and activation of MLCP, relaxation was 
measured as inhibition of maximal contraction in response to 0.5 µM Ca
2+
.  Under these 
experimental conditions, the effect of cGMP/PKG on Ca
2+
 is precluded and reflects stimulation 
of MLCP activity, probably via telokin.  Since termination of cGMP/PKG signaling is different in 
antrum and fundus and depends on the expression of PDE5 (see next chapter), 8-Br-cGMP, a 
non-hydrolyzable analog of cGMP, was used to induce muscle relaxation.  Treatment of 
permeabilized muscle cells with 0.5 µM Ca
2+
 caused contraction that was similar in muscle cells 
from antrum (243% decrease in cell length from a basal cell length of 853 µm) and fundus 
(262% decrease in cell length from a basal cell length of 924 µm).  Pretreatment of cells with 
8-Br-cGMP (1mM) caused relaxation (i.e., inhibition of contraction) that was concentration-
dependent (EC50: antrum, 83 µM; fundus, 124).  Relaxation was significantly higher in antrum 
compared to fundus at all concentrations of 8-Br-cGMP.  The maximal response was significantly 
greater in muscle cells from antrum (764% relaxation) compared to muscle cells from fundus 
(473% relaxation) (figure 25 A).  However, stimulation of PKG activity in response to 8-Br-
cGMP was similar in antrum (-GMP/+cGMP activity ratio, 2.40.4) and fundus (-cGMP/+cGMP 
activity ratio, 2.20.3) suggesting that lower relaxation in fundus was not due to cGMP 
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degradation via PDE5 or efflux via MRP5, and possibly reflects lower expression of telokin 
(figure 25 B).    
6.3       Telokin-dependent stimulation of MLCP activity   
Previous studies have demonstrated that PKG-mediated phosphorylation of telokin at 
Ser
13
 greatly augments the ability of telokin to stimulate MLCP activity.   We tested the role of 
telokin in cGMP/PKG-mediated relaxation by overexpressing cultured muscle cells with wild 
type or phosphorylation-deficient telokin (S13A).  Relaxation in response to 8-Br-cGMP was 
measured as decrease in Ca
2+
 (0.5 µM)-induced MLC20 phosphorylation.   Treatment of cells, 
containing either wild type or telokin S13A mutant with 0.5 µM Ca
2+ 
for 1 minute significantly 
augmented phosphorylation of MLC20 at Ser
19
.  The extent of phosphorylation was similar in 
both antrum and fundus and consistent with similar levels of contraction as described above.  
Pretreatment of cells with 8-Br-cGMP inhibited MLC20 phosphorylation in both fundus (485% 
inhibition) and antrum (786% inhibition) suggesting dephosphorylation of MLC20 due to 
activation of MLCP. The inhibitory effect 8-Br-cGMP was significantly (p<0.05, n=4) higher in 
antrum compared to fundus, and reflects higher expression of telokin in antrum compared to 
fundus (figures 26 and 27).  
The inhibitory effect of 8-Br-cGMP on MLC20 phosphorylation was significantly 
attenuated in cells expressing telokin S13A suggesting that the effect of 8-Br-cGMP was due to 
augmentation of MLCP activity via phosphorylation of telokin at Ser
13
.  Importantly, in the 
presence of telokin (S13A), the inhibitory effect of 8-Br-cGMP was not significantly different 
between antrum and fundus (figures 26 and 27).  These results provide conclusive evidence for 
the involvement of telokin in the activation of MLCP and MLC20 dephosphorylaiton.  Higher 
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expressions of telokin and MLCP activity in antrum also correlate with the phasic phenotype of 
this muscle, where rapid contractions and relaxations are needed for optimal organ function.   
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Figure 24.  Expression of telokin.  Total RNA isolated from cultured (first passage) muscle cells 
from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The cDNA was 
amplified with specific primers for telokin.  The sequences of specific primers are listed in Table 
1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure RNA levels of 
telokin.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume 
containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR reactions were performed 
in triplicate. Each primer set generated only one PCR product (69 bp), and the identity and 
integrity of these products were confirmed by electrophoresis in agarose gel in the presence of 
ethidium bromide and sequencing of the individual bands.   Standard curves for each amplicon 
were generated from a dilution series of cDNA and results were quantified and reported using the 
2
−ΔΔCT 
method based on GAPDH amplification.  Relative quantification of a target gene in 
relation to reference gene was calculated on the basis of delta delta CT values.  Results 
demonstrated that mRNA levels of telokin are significantly higher in antrum compared to fundus  
Inset: Representative western blot results of telokin  expression.  Cell lysates containing equal 
amounts of total proteins were separated with SDS-PAGE and expression of telokin was analyzed 
using selective antibody for telokin.  Membranes were reblotted to measure β-actin. Protein bands 
were visualized with enhanced chemiluminescence, images were quantified and densitometric 
values were calculated after normalization to β-actin density.  Results are expressed as fold 
increase over the expression of telokin in fundus.   Values represent the means SEM of 3 
separate experiments. **p<0.001 versus fundus. 
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Figure 25.  8-Br-cGMP-induced muscle relaxation and PKG activity.  A.  Relaxation of 
dispersed muscle cells from antrum and fundus in response to different concentrations of 8-Br-
cGMP was measured by scanning micrometry as decrease in Ca
2+
-induced contraction.  
Contraction in response to 0.5 µM Ca
2+
 was measured in permeabilized muscle cells.  
Contraction was similar in muscle cells from antrum (243% decrease in cell length from a basal 
cell length of 853 µm) and fundus (262% decrease in cell length from a basal cell length of 
924 µm).  8-Br-cGMP caused relaxation that was concentration-dependent in both antrum and 
fundus and the relaxation was greater in antrum compared to fundus.  The maximal response to 1 
mM 8-Br-cGMP that was significantly greater in antrum (764% relaxation) compared to muscle 
cells from fundus (473% relaxation).  Values represent the means SEM of 4 separate 
experiments.  *p<0.05 significant increase in relaxation in antrum versus relaxation in fundus.  B.  
One milliliter of cell suspension (2 x 10
6
 cells/ml) of freshly dispersed muscle cells from antrum 
and fundus was treated with 8-Br-cGMP (1 mM) for 10 min.  The cells were homogenized in the 
lysis buffer and the protein content in the supernatants was measured.  PKG activity was 
measured in the presence or absence of cGMP using a specific substrate RKRSRAE and 
[
32
P]ATP, and the results are expressed as the ratio of activity in the absence or presence of 
cGMP.  8-Br-cGMP-stimulated PKG activity was similar in antrum and fundus.  Values represent 
the means SEM of 3 separate experiments.   
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Figure 26.  Inhibition of Ca
2+
-induced MLC20 phosphorylation by 8-Br-cGMP and the 
effect of telokin in muscle cells from fundus.  Cultured muscle cells from fundus 
overexpressing wild type telokin or phosphorylation-deficient telokin (telokin S13A) were 
permeabilized, pretreated with 8-Br-cGMP (1 mM) and then treated with 0.5 µM Ca
2+
.  MLC20 
phosphorylation was measured in MLC20 imunoprecipitates using antibody specific for phospho-
Ser
19
 MLC20 by immunoblot analysis. Densitometric values were calculated after normalization 
to MLC20 density and the results expressed as percent of control density.  Ca
2+
-induced MLC20 
phosphorylation was significantly inhibited in cells expressing wild type telokin, but not in cells 
expressing telokin S13A.  Values represent the means SEM of 3 separate experiments.  
**p<0.001 significant increase in MLC20 phosphorylation by Ca
2+
, ##p<0.05 significant 
inhibition of Ca
2+
-induced MLC20 phosphorylation by 8-Br-cGMP. 
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Figure 27.  Inhibition of Ca
2+
-induced MLC20 phosphorylation by 8-Br-cGMP and the 
effect of telokin in muscle cells from antrum.  Cultures muscle cells from antrum 
overexpressing wild type telokin or phosphorylation-deficient telokin (telokin S13A) were 
permeabilized, pretreated with 8-Br-cGMP (1 mM) and then treated with 0.5 µM Ca
2+
.  MLC20 
phosphorylation was measured in MLC20 imunoprecipitates using antibody specific for phospho-
Ser
19
 MLC20 by immunoblot analysis. Densitometric values were calculated after normalization 
to MLC20 density and the results expressed as percent of control density.  Ca
2+
-induced MLC20 
phosphorylation was significantly inhibited in cells expressing wild type telokin, but not in cells 
expressing telokin S13A.  The inhibition of MLC20 phosphorylation was significantly greater in 
antrum (786% inhibition) compared to fundus (485% inhibition) (compare Figs 26 and 27).  
Values represent the means SEM of 3 separate experiments.  **p<0.001 significant increase in 
MLC20 phosphorylation by Ca
2+
, ## p<0.05 significant inhibition of Ca
2+
-induced MLC20 
phosphorylation by 8-Br-cGMP. 
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CHAPTER 7 
REGULATION OF CYCLIC GMP LEVELS AND MUSCLE RELAXATION IN 
ANTRUM AND FUNDUS 
116 
 
In the gastrointestinal smooth muscle, the main inhibitory transmitters vasoactive 
intestinal peptide (VIP) and nitric oxide (NO) induce relaxation through the generation of cAMP 
and cGMP, and activation of cAMP-dependent protein kinase (PKA) and cGMP-dependent 
protein kinase (PKG).  Although generation of both nucleotides and activation of both kinases are 
the physiological norm, studies in mice lacking sGC or PKGI suggest an important role for 
sGC/cGMP/PKG pathway in smooth muscle relaxation 
106-108
. The strength and duration of 
cGMP signaling is regulated by its degradation into inactive 5′GMP via cGMP-specific PDE5, 
and efflux via ATP-dependent transporter, MRP5.  We postulated that the termination of cGMP 
effect by both PDE5 and MRP5 in tonic muscle could contribute to rapid return to tonic 
contractile phenotype following a relaxation.     
7.1       PDE5 Expression and Activity   
Expression of PDE5, by both qRT-PCR and western blot, and stimulation of PDE5 
activity in response to NO-donor, s-nitrosoglutathione (GSNO), were determined in muscle cells 
from antrum and fundus.  PDE5 mRNA was expressed in both antrum and fundus and the 
expression was 2-fold higher in fundus compared to antrum (figure 28).  PDE5 protein expression 
117 
was examined in the two regions of the stomach by western blot using selective antibody to 
PDE5A, the smooth muscle predominant isoform
109
.  Results confirmed the expression of PDE5 
of expected size (100 kDa) in the homogenates of smooth muscle cells from both antrum and 
fundus (figure 28). Comparing the densities of protein bands in the two regions revealed a 3-fold 
higher expression of PDE5 in fundus compared to antrum and this is consistent with the higher 
expression of PDE5 mRNA in fundus compared to antrum (Figure 28). 
Basal and GSNO-stimulated PDE5 activity was measured by ion-exchange 
chromatography using [
3
H]cGMP as substrate.  Although, the expression levels are different, 
basal PDE5 activity was not significantly different in antrum (23856 cpm/mg protein) and 
fundus (28545 cpm/mg protein).  Treatment of dispersed muscle cells with GSNO increased 
PDE5 activity in a concentration-dependent fashion in antrum and fundus.  Stimulation of PDE5 
activity was significantly higher at concentrations above 10 nM of GSNO in fundus compared to 
antrum (Figure 29A).  The maximal stimulation was also significantly higher (p<0.05, n=6) in 
fundus (3212 245 cpm/mg protein) compared to antrum (2189310 cpm/mg protein). 
Further evidence for higher PDE5 activity in fundus was obtained by measurements of 
cGMP levels in response to GSNO. GSNO increased cGMP levels in muscle cells from both 
regions in a concentration-dependent fashion. Basal levels of cGMP are similar in antrum 
(0.280.04 pmol/mg protein) and fundus (0.210.03pmol/mg protein).  However, GSNO-
stimulated cGMP levels were significantly lower in fundus compared to antrum. The maximal 
stimulation was also significantly lower in fundus (573% increase above basal levels) compared 
to antrum (764% increase above basal levels of cGMP) (Figure 29 B).  The results are consistent 
with the higher PDE5 expression and activity in fundus compared to antrum. 
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Figure 28.  Expression of PDE5A.  Total RNA isolated from cultured (first passage) muscle 
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The cDNA was 
amplified with specific primers for PDE5A.  The sequences of specific primers are listed in Table 
1.  Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels 
of PDE5A.  For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume 
containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR reactions were performed 
in triplicate. Each primer set generated only one PCR product (65bp), and the identity and 
integrity of these products were confirmed by electrophoresis in agarose gel in the presence of 
ethidium bromide and sequencing of the individual bands.   Standard curves for each amplicon 
were generated from a dilution series of cDNA and results were quantified and reported using the 
2
−ΔΔCT
 method based on GAPDH amplification.  Relative quantification of a target gene in 
relation to reference gene was calculated on the basis of delta delta CT values.  Results 
demonstrated that mRNA levels of PDE5A are significantly higher in fundus compared to 
antrum.  Inset: Representative western blot results of PDE5A expression.  Cell lysates containing 
equal amounts of total proteins were separated with SDS-PAGE and expression of PDE5A was 
analyzed using selective antibody for PDE5A.  Membranes were reblotted to measure β-actin. 
Protein bands were visualized with enhanced chemiluminescence, images were quantified and 
densitometric values were calculated after normalization to β-actin density.  Results are expressed 
as fold increase over the expression of PDE5 in antrum.   Values represent the means SEM of 3 
separate experiments. **p<0.001 versus antrum. 
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Figure 29.  Stimulation of PDE5 activity and cGMP formation by GSNO.  A.  One milliliter 
of cell suspension (2x 10
6
 cells/ml) of freshly dispersed muscle cells from antrum and fundus was 
treated with different concentrations of s-nitrosoglutathione (GSNO), an NO-donor, for 60 s.  The 
cells were homogenized in the lysis buffer and the protein content in the supernatants was 
measured.  PDE5 was immunoprecipitated from lysates containing equal amount of protein and 
the activity was measured in immunoprecipitates by liquid chromatography using [3H]cGMP as 
substrate.  The amount of radioactivity in the elutes was measured by liquid scintillation and the 
results are expressed as counts per milligram protein per minute.  GSNO stimulated PDE5 
activity in a concentration-dependent manner and the stimulation was significantly higher in 
fundus compared to antrum.  Values represent the means SEM of 5-6 separate experiments.  
*p<0.05 significant increase in PDE5 activity in fundus compared to antrum.  B.  One milliliter of 
cell suspension (2 x 10
6
 cells/ml) of freshly dispersed muscle cells from antrum and fundus was 
treated with different concentrations of s-nitrosoglutathione (GSNO) for 60 s and the reaction was 
terminated with 10% trichloroacetic acid.  Cyclic GMP was measured by radioimmuno assay 
using [
125
I]cGMP and the results were expressed as percent increase above basal levels (basal 
levels in antrum 0.280.04 pmol/mg protein; basal level in fundus 0.210.03pmol/mg protein).  
GSNO stimulated cGMP levels in a concentration-dependent manner and the stimulation was 
significantly lower in fundus compared to antrum. Values represent the means SEM of 5 
separate experiments.  *p<0.05 significant lower cGMP levels in fundus compared to antrum. 
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7.2       MRP5 Expression   
Another important mechanism in keeping intracellular cyclic nucleotides within narrow 
limits is their efflux into the extracellular space via ATP-dependent multidrug resistant proteins 
(MRPs).  MRP5 has been identified as a cGMP export pump in the heart and vasculature, but its 
expression and function in gastrointestinal smooth muscle are not known. Specific primers for 
MRP5 were designed based on corresponding conserved sequences in human, rat, and mouse 
cDNAs (Table 1).  MRP5 was detected by RT-PCR using RNA extracted from cultures of whole 
gastric smooth muscle cells in first passage.  Cloning and sequence analysis of the RT-PCR 
product of MRP5 in the stomach was 98% similar to the corresponding amino acid sequences of 
human.  Expression of MRP5 mRNA was higher in fundus compared to antrum (Figure 30). 
MRP5 protein expression was examined in the two regions of the stomach by western blot 
using selective antibody to MRP5.  Results confirmed the expression of MRP5 of expected size 
(185 kDa) in the homogenates of smooth muscle cells from both antrum and fundus. Comparing 
the densities of protein bands in the two regions revealed a 5-fold higher expression of MRP5 in 
fundus compared to antrum (Figure 30).  
7.3       cGMP efflux   
The function of MRP5 was analyzed by measuring intra- and extracellular cGMP levels in 
response to GSNO.  To exclude the involvement of PDE5 and examine the singular contribution 
of MRP5 in the regulation of intracellular cGMP levels, experiments were done in the presence of 
a non-selective PDE inhibitor, IBMX (100 µM).  Under these experimental conditions, changes 
in intracellular cGMP reflect efflux of cGMP, probably via MRP5.  GSNO caused an increase in 
both intra- (14610% increase above basal level of 0.420.05 pmol/mg protein) and extracellular 
123 
(655% increase above basal level of 0.160.03 pmol/mg protein) cGMP levels in antrum, and 
the increase in intracellular cGMP was greater compared to extracellular cGMP levels.  GSNO 
also caused an increase in both intra- (889 above basal level of 0.380.04 pmol/mg protein) and 
extracellular (17615% increase above basal level of 0.180.03 pmol/mg protein) cGMP levels 
in fundus, and the increase in extracellular cGMP was greater compared to intracellular cGMP 
levels (Figure 31). Moreover, GSNO-induced cGMP efflux was blocked in cultured muscle cells 
tranfected with MRP5 siRNA from both antrum and fundus (figure 32) but not in muscle cells 
tranfected with control siRNA (figure33). The results are consistent with the higher expression of 
cGMP-specific MRP5 in fundus compared to antrum and also consistent with the tonic phenotype 
of fundus muscle where rapid restoration of contractile function is required for optimal function.   
7.4       NO-induced smooth muscle relaxation   
To examine the role of PDE5 and MRP5 pathways in the regulation of muscle function, 
relaxation of muscle cells from antrum and fundus was measured by scanning micrometry.  
Muscle relaxation was measured as inhibition of ACh-induced contraction in response to GSNO 
as described previously. GSNO-induced muscle relaxation was concentration-dependent in both 
antrum and fundus (Figure 34).  Relaxation was significantly lower in fundus compared to antrum 
and the maximal response was 733% in antrum and 584% in fundus (Figure 34).  The results 
are consistent with the higher PDE5 and MRP5 functions resulting in lower intracellular cGMP 
levels in muscle cells from fundus compared to cells from antrum.   
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Figure 30.  Expression of MRP5.  A.  Total RNA isolated from cultured (first passage) muscle 
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.  The cDNA was 
amplified with specific primers for MRP5.  The sequences of specific primers are listed in Table 
1.  The primer set generated only one PCR product (151bp), and the identity and integrity of these 
products were confirmed by electrophoresis in agarose gel in the presence of ethidium bromide 
and sequencing of the individual band.   Results demonstrated that mRNA levels of MRP5 are 
higher in fundus compared to antrum.  B. Representative western blot results of MRP5 
expression.  Cell lysates containing equal amounts of total proteins were separated with SDS-
PAGE and expression of MRP5 was analyzed using selective antibody for MRP5.  Membranes 
were reblotted to measure β-actin. Protein bands were visualized with enhanced 
chemiluminescence, images were quantified and densitometric values were calculated after 
normalization to β-actin density.  Densitometric values showed that MRP5 expressin was 4-fold 
higher in fundus compared to antrum.  Values represent the means SEM of 3 separate 
experiments. **p<0.001 versus antrum. 
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Figure 31.  Stimulation of cGMP efflux by GSNO.  One milliliter of cell suspension (2 x 10
6
 
cells/ml) of freshly dispersed muscle cells from antrum and fundus was treated with GSNO for 10 
min in the presence of non-specific PDE inhibitor, 100 µM isobutylmethyl xanthine (IBMX).  
Under these experimental conditions, the effect of PDE5 on cGMP degradation was precluded.   
Cyclic GMP was measured by radioimmuno assay using [
125
I]cGMP in the cell pellet and 
supernatant to reflect intracellular and extracellular cGMP levels, respectively.   The results are 
expressed as percent increase above basal level (antrum: basal intracellular 0.420.05 pmol/mg 
protein; basal extracellular 0.160.03 pmol/mg protein; fundus: basal intracellular 0.380.04 
pmol/mg protein; basal extracellular 0.180.03 pmol/mg protein).  GSNO stimulated both intra- 
and extracellular cGMP levels in antrum and fundus.  The increase in intracellular levels was 
higher in antrum compared to extracelluar levels.  In contrast, increase in extracellular levels was 
higher in fundus compared to intracelluar levels.  Values represent the means SEM of 5 separate 
experiments.  **p<0.05 significant increase in cGMP levels by GSNO above basal levels; 
##p<0.05 significant increase in extracellular cGMP in fundus compared to antrum. 
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Figure 32.  cGMP efflux in cells transfecrted with MRP5 siRNA.  Cultures muscle cells 
transfected with MRP5 siRNA were treated with GSNO for 10 min in the presence of non-
specific PDE inhibitor, 100 µM isobutylmethyl xanthine (IBMX).  Cyclic cGMP was measured 
by radioimmuno assay using [
125
I]cGMP in the cell pellet and supernatant to reflect intracellular 
and extracellular cGMP levels, respectively.   The results are expressed as percent increase above 
basal level (antrum: basal intracellular 0.380.04 pmol/mg protein; basal extracellular 0.13 0.02 
pmol/mg protein; fundus: basal intracellular 0.35 0.04 pmol/mg protein; basal extracellular 
0.160.02 pmol/mg protein).  GSNO-stimulated extracellular cGMP levels were abolished in 
cells transfected with MRP5 siRNA in antrum and fundus.  Values represent the means SEM of 
5 separate experiments.  **p<0.001 significant increase in cGMP levels by GSNO above basal 
levels.  Left panel: MRP5 expression in cells transfected with control siRNA or MRP5siRNA 
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Figure 33.  cGMP efflux by in cells transfecrted with control siRNA.  Cultures muscle cells 
transfected with control siRNA were treated with GSNO for 10 min in the presence of non-
specific PDE inhibitor, 100 µM isobutylmethyl xanthine (IBMX).  Cyclic cGMP was measured 
by radioimmuno assay using [
125
I]cGMP in the cell pellet and supernatant to reflect intracellular 
and extracellular cGMP levels, respectively.   The results are expressed as percent increase above 
basal level (antrum: basal intracellular 0.34 0.03 pmol/mg protein; basal extracellular 0.11 0.01 
pmol/mg protein; fundus: basal intracellular 0.28 0.02 pmol/mg protein; basal extracellular 
0.140.02 pmol/mg protein).  GSNO stimulated both intra- and extracellular cGMP levels in 
antrum and fundus.  The increase in intracellular levels was higher in antrum compared to 
extracelluar levels.  In contrast, increase in extracellular levels was higher in fundus compared to 
intracelluar levels.  Values represent the means SEM of 5 separate experiments.  *p<0.05 
significant increase in cGMP levels by GSNO above basal levels; ##p<0.05 significant increase 
in extracellular cGMP in fundus compared to antrum. 
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Figure 34. GSNO-induced muscle relaxation.  Relaxation of dispersed muscle cells from 
antrum and fundus in response to different concentrations of s-nitrosoglutathione (GSNO) was 
measured by scanning micrometry as decrease in ACh-induced contraction.  Contraction was 
measured in response to maximal concentrations of ACh (0.1 m) at 30 s as decrease in muscle 
control cell length (antrum:  control cell length 983 m; fundus: control cell length 914 m).  
Contraction was similar in muscle cells from antrum (283% decrease) and fundus (292% 
decrease).  GSNO caused relaxation that was concentration-dependent in both antrum and fundus 
and the relaxation was greater in antrum compared to fundus.  The maximal response to 10 M 
GSNO was significantly greater in antrum (733% relaxation) compared to muscle cells from 
fundus (584% relaxation).  Values represent the means SEM of 4 separate experiments.  
*p<0.05 significant increase in relaxation in antrum versus relaxation in fundus.  
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CHAPTER 8 
DISCUSSION 
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Smooth muscle cells are the fundamental structural and functional units of the gastrointestinal 
system and exhibit distinct contractile phenotypes.  The underlying features of phasic muscles (e.g., 
distal stomach and intestine) are the ability to generate rhythmic contractions and relaxations, while 
tonic muscles (e.g., sphincters and proximal stomach) have sustained tone and relax transiently in 
response to relaxant transmitters.  Contractile agonists increase MLC20 phosphorylation by 
Ca
2+
/CaM-dependent stimulation of MLCK and RhoA-dependent inhibition of MLCP activity.  
Relaxant agonists decrease MLC20 phosphorylation either by decreasing Ca
2+
 levels or increasing 
MLCP activity via PKA and PKG-dependent pathways.  Although MLC20 phosphorylation is a 
prerequisite of contraction in both muscle types, the biochemical basis of phasic and tonic phenotypes 
of smooth muscle is not clear and is the major question of inquiry in the present study.  The objective 
of this project is to determine whether the expression of contractile protein isoforms, the regulation of 
Ca
2+
/calmodulin-dependent MLCK and Rho kinase/ZIPK-dependent MLCP activity, and the 
termination of cGMP signaling are different in phasic and tonic smooth muscle.  Using biochemical, 
molecular and functional approaches, and antrum (distal stomach) and fundus (proximal stomach) of 
rabbit stomach as models of phasic and tonic smooth muscle, respectively, the present study 
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characterized the differences in the signaling pathways that regulate MLCK and MLCP activities and 
cGMP levels.  Expression of contractile proteins is tissue specific with higher levels of caldesmon, 
calponin, tropomyosin and smoothelin A expression in antrum compared to fundus.  In muscle cells 
from antrum MLCK activity is under feedback negative control by higher expression and activation 
of CaMKKβ/AMPK pathway, and MLCP is positively regulated by higher expression of telokin, an 
endogenous MLCP activator.  In muscle cells from fundus, in contrast, MLCP activity is suppressed 
by higher expression and activation of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17 pathways, and 
cGMP/PKG pathway is attenuated by rapid degradation and efflux of cGMP via higher expression 
PDE5 and MRP5, respectively (figure 33).  These differences in the biochemical pathways highly 
correlate with the functional phasic phenotype of antrum and tonic phenotype of fundus.  
8.1   Differences in the contractile protein content and isoforms and their associated 
proteins 
It is hypothesized that differences in the mechanical behavior between tonic and phasic 
smooth muscles could be due to differences in the contractile proteins themselves; actin, myosin 
and their associated proteins such as caldesmon and calponin. Previous studies
110,111
 have 
demonstrated that the tonic muscle myosin has a greater affinity for MgADP at low 
phosphorylation levels than the phasic myosin, a property that aids in maintaining the developed 
force in tonic muscles. In this study, we investigated the content and isoform distribution of the 
main contractile proteins; actin and myosin, and the thin filament associated proteins; 
tropomyosin, caldesom, calponin, and smoothelin in smooth muscles of the antrum and fundus.  
The results showed that the expression of contractile proteins is tissue specific with higher levels 
of caldesmon, calponin, tropomyosin and smoothelin A expression in antrum compared to 
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fundus.   These results are consistent with the results previous studies using different models of 
phasic and tonic tissues in different species
6,112,113
. 
8.1.1    Myosin isoforms   
Myosin molecule is a hexamer with 2 subunits of smooth muscle-specific myosin heavy 
chain (MHC), a pair of 17 kDa MLC and a pair 20 kDa MLC (MLC20). Alternative RNA 
processing of a single gene generates four isoforms of MHC.  Alternate splicing of a 21-
neoclutide exon at the 5‟ end of the gene results in the presence (SMB isoform) or absence (SMA 
isoform) of a seven-amino acid insert at the globular head region of the MHC molecule
114
. In 
addition, alternate splicing of a 39-neoclutide exon in the non-helical portion of the 3‟ end of the 
gene coding for 9 unique amino acids at the COOH terminus and an in-frame stop codon results 
in a molecule that is 34 amino acids shorter (SM2) than the alternately spliced isoform (SM1)
115
. 
It has been suggested that differential expression of myosin heavy chain isoforms may 
influence smooth muscle contractility
116
, Chi et al., for example, have found that ablation of 
smooth muscle myosin heavy chain SM2 increases smooth muscle contraction
117
. Others have 
found a positive correlation between SM1 myosin content and maximal velocity of muscle 
shortening (Vmax) in rat uterine smooth muscle
116
. In the present study, we could detect SM1 and 
SM2 isoforms only in antrum, and that SM1 expression was greater than SM2.  
Our results are consistent with this proposed function of these MHC isoforms in smooth 
muscle.  In antrum, higher SM1 expression might be pertinent with the rapid crossbridge cycling 
and as a result smooth muscle shortening and contraction that is needed in this region of the 
stomach which is characterized by rapid contraction and relaxation cycles.  In addition, greater 
SM2 expression in this distal part of the stomach might be of importance in preventing the 
development of any basal tone, and thus leading to rapid fade of the stimulated contraction in the 
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phasic smooth muscles of the antrum. Eddinger et al.,
75
, on the other hand, reported 
approximately equal amounts of both SM1 and SM2 MHC isoforms in all regions of the rabbit 
stomach. However, these measurements were made on tissue pieces taken from different 
locations along the greater curvature of the stomach and this expression pattern might differ at the 
cellular level. 
Regarding MHC isoforms with (SMB) and without (SMA) the seven-amino acid insert at 
the globular head region of the MHC molecule, Kelley et al. 
118
 showed that the phasic chicken 
gizzard, but not the tonic chicken aortic smooth muscle, contains myosin with the seven-amino 
acid insert and showed that the presence of SMB isoform correlates with a higher velocity of 
movement of actin filaments over myosin heads in the in vitro motility assay and a higher actin-
activated myosin ATPase activity.  Moreover, DiSanto et al., 
119
 howed that the inserted myosin 
mRNA level increases in more distal muscular arteries that show phasic contractions compared to 
aorta which primarily possesses tonic activity.  
By measuring mRNA expression levels in cultured gastric smooth muscle cells, we 
demonstrated that antrum contains greater SMB but lower SMA mRNA contents than fundus. 
This is consistent with the previous reports and with the proposed functional role of these 
isoforms with actomyosin ATPase activity and maximum shortening velocity, which are greater 
in phasic smooth muscles than in tonic ones.  Further work is needed to examine the correlation 
between protein expression of each of these different isoforms and RNA expression pattern. 
It is important to mention that other myosin II isoforms might add a complexity to the 
above mentioned differences between phasic and tonic smooth muscles. For example, it is known 
that non-muscle myosin (NMII A, B, and C) interacts with actin and converts the chemical 
energy from ATP hydrolysis to force
120
. The expression of non-muscle myosin isoforms, NMIIA 
and NMIIB, has been well documented to be different between phasic and tonic smooth muscle. 
138 
It has been reported that NMIIA isoform is predominating in the phasic mouse bladder muscle, 
while NMIIB is the major isoform in the tonic aorta
121
. Whether these non-muscle myosins are 
regionally distributed in the GI tract or have a functional contribution to muscle contractility is 
not known yet. 
8.1.2    Actin isoforms    
Of the thin filaments, actin stands as the major constituent and plays an important role, 
with myosin, in crossbridge formation. Three major actin isoforms are expressed in smooth 
muscle; α, β, and γ. The β -isoform is a cytoskeletal actin, whereas α and γ isoforms colocalize 
within the contractile apparatus. We found that the relative content of β-actin is similar in the 
antrum and fundus. However, muscle cells from fundus contain more α-actin but less γ-actin than 
antrum. Our results are in agreement with the early data of Fatigati and Murphy 
122
 who showed 
that α-actin is mainly found in arterial smooth muscle, whereas γ -actin usually predominates in 
visceral smooth muscle. Szymanski et al., have also reported about two to three times more α-
actin in the lower esophageal sphincter than in the esophageal body, whereas γ -actin was ~43% 
more in the esophageal body compared to lower esophageal sphincter
100
. Future functional 
studies might correlate these different regional distributions of the different actin isoforms to 
smooth muscle contractility. 
8.1.3    Caldesmon, calponin, and tropomyosin   
Besides actin, it is strongly believed now that the thin-filament-associated proteins 
regulate actomyosin ATPase activity and thus modulate the rapid cross-bridge cycling formed by 
actomyosin interaction; the essential event of muscle contraction.  In the present study, we show 
that there is a greater abundance of tropomyosin, calponin, and caldesmon in antrum compared to 
fundus.  It has been shown that caldesmon and calponin exert an inhibitory effect on actin-
activated myosin ATPase activity and suppress contraction in a Ca
2+
-regulated manner
56,59,60
. 
139 
Phosphorylation of caldesmon by kinases, mainly PKC and MAPK, or binding of Ca
2+
/CaM to 
caldesmon, although with low affinity, dissociates caldesmon from F-actin and thus removes the 
inhibitory effect of caldesmon on actomyosin ATPase by allowing myosin heads to interact with 
the freed actin filaments and so muscle to contract
123,124
. 
Consistent with our data, Haeberle et al., 
125
 have shown that caldesmon content is higher 
in smooth muscles from rabbit ileum, guinea pig taenia coli, and rat uterus than in muscles 
isolated from bovine aorta or porcine carotid arteries. In addition, Caldesmon level in the extreme 
example of phasic muscles, chicken gizzard smooth muscle, was reported to be about twofold 
higher than in vascular smooth muscle 
124,125
. 
Regarding calponin , the recent report of faster unloaded shortening velocity in smooth 
muscle of calponin knock-out mice is consistent with the suggested negative regulation of the 
cross bridge cycle by calponin
126
. Calponin‟s inhibitory effect on actomyosin ATPase was found 
to be removed via either phosphorylation by PKC or Ca
2+
-CaM-dependent kinase II 
56
 or binding 
to CaM
127
. 
Goyal and coworkers reported similar calponin content in both the phasic esophageal 
body and the tonic lower esophageal sphincter smooth muscles
100
. The discrepancy between this 
data and our calponin data could be simply a consequence of species and tissue differences, but 
additional work is needed to demonstrate this possibility. 
In parallel with the proposed roles for caldesmon and calponin, it was proposed that 
tropomyosin might impose an inhibitory effect on myosin ATPase activity by covering and 
spanning actin monomers. The removal of this inhibitory regulation, upon smooth muscle 
activation, displaces tropomyosin from myosin-binding sites on actin leading to cooperative 
actomyosin cross-bridge formation and muscle contraction
48
. Our data, which shows higher 
contents of caldesmon, calponin and tropomyosin in antrum might fit with the suggested roles for 
140 
these thin filament-associated proteins in facilitating the accelerated relaxation and preventing the 
generation of basal tone in phasic smooth muscle.  
8.1.4    Smoothelin  
Smoothelin is another α-actin-binding protein and is a constituent of the cytoskeleton 
which is specific for smooth muscle cells in a broad range of species. It is encoded by a single-
copy gene via dual promoter system that generates two major isoforms; A (59 kDa) and B (110 
kDa) 
128
. Although our knowledge about its function is still incomplete, previous embryological 
129
 and knock-out 
66
 studies have revealed that lack of smoothelin leads to a decreased contractile 
potential of smooth muscle.  It was proposed that smoothelin A isoform is predominantly 
expressed in visceral tissues while B isoform is the vascular isoform of smoothelin, although not 
all vascular smooth muscle cells in arterial media express smoothelin. For example, in elastic 
arteries, such as the aorta, the percentage of smoothelin-expressing smooth muscle is lower than 
in muscular arteries, such as the femoral artery 
64
. Consistent with those previous reports, we 
found that mRNA levels of smoothelin A are greater in antrum while smoothelin B mRNA levels 
are higher in fundus. More research on other different types of phasic and tonic smooth muscle 
tissues is needed to flourish literature in this aspect. In addition, better understanding of 
smoothelin function might be the link to its differential expression in various smooth muscle 
types. 
8.2     Differences in the regulation of MLCK activity 
The major mechanism responsible for contraction in smooth muscle is the 
phosphorylation of MLC20 by MLCK. Phosphorylation of MLC20 removes its inhibitory effect on 
actomyosin ATPase and increases cross-bridge cycling that eventually leads to muscle 
141 
contraction 
23,31,130,131
. It is now well-established that MLCK interacts with Ca
2+
/CaM with a very 
high affinity, and then the formed Ca
2+
/CaM-MLCK complex phosphorylates MLC20. 
Our results show that both mRNA and protein expression levels of MLCK are higher in 
antrum compared to fundus of rabbit stomach. Our results seem to be in parallel with the results 
of Szymanski et al., who found that MLCK content in esophageal body was approximately 
threefold higher and phosphorylation of MLC20 was approximately fivefold faster than in lower 
esophageal sphincter
99
. However, in spite of greater MLCK expression in antrum, ACh-
stimulated activity of MLCK was similar in both regions. Moreover, contraction of permeabilized 
muscle in response to 0.5µM Ca
2+
 was similar in cells from the two regions, suggesting that Ca
2+
-
dependent MLCK activity is similar in both regions. These results raise the possibility that 
MLCK activity may be selectively suppressed in antrum via negative feedback mechanisms 
involving other kinases such as AMPK. 
It is important to note that changes in [Ca
2+
]i do not always lead to proportional increases 
in MLCK activation. At longer time after initiation of neural stimulation, there is an apparent 
desensitization of the kinase to Ca
2+
. This desensitization occurs when MLCK is phosphorylated 
at the C terminus of its CaM-binding sequence that would decrease the affinity of the kinase for 
Ca
2+
/CaM. This phosphorylation was shown previously to be Ca
2+
-dependent 
131
. Recent 
evidence indicates that it is mediated by Ca
2+
-dependent activation of CaM-dependent protein 
kinase kinase-β, CaMKK-β, via Gq-coupled receptors104. CaMKK-β in turn phosphorylates and 
activates AMPK. Although MLC20 is not a direct downstream physiological substrate of AMPK 
132
 but still it desensitizes smooth muscle by phosphorylating MLCK at Ser
815
 and thus leading to 
its inhibition
29
. Moreover, if the concentration of AMP increases sufficiently in the contracting 
muscle, AMP can also directly activate AMPK. So, both Ca
2+
-dependent and AMP-stimulated 
feedback mechanisms would thus diminish MLCK activity. 
142 
AMP-activated protein kinase (AMPK) is a Ser/Thr kinase heterotrimer consisting of a 
catalytic α-subunit and two regulatory subunits, β and γ. It acts as an energy sensor at both 
cellular and systemic levels in mammals
133,134
. Phosphorylation of Thr
172
 in the activation loop of 
the catalytic α-subunit 134 by upstream kinases (e.g., CaMKK-β) activates AMPK which in turn 
decreases ATP consumption and stimulates ATP-producing processes 
133
. AMPK is 
dephosphorylated and deactivated by protein phosphatase-2C (PP2C) 
105
. 
There are multiple isoforms of AMPK that are encoded by different genes; two isoforms 
of the catalytic α subunit (α1 and α2), two isoforms of the β subunit (β1 and β2), and three 
isoforms of the γ subunit (γ1, γ2, γ3), that can lead to the formation of 12 different complexes 
with differing properties 
105
.  
α1 subunit is ubiquitously expressed and localized predominantly to the cytosol and hence 
likely to phosphorylate cytosolic and plasma membrane substrates, whereas the α2 subunit is 
expressed predominantly in skeletal muscle, liver and cardiac muscle, where it is found in both 
cytosol and nuclei 
105
. As the primary AMPK isozyme, α1 is found in pulmonary arterial smooth 
muscle 
135
, carotid smooth muscle 
136
, vascular endothelial cells and mouse aorta
137
. 
Our results showed that both protein and mRNA expression of AMPK1 was greater in 
antrum than in fundus. Functionally, ACh-stimulated AMPK activity was also greater in muscle 
cells from antrum compared to fundus. AMPK activity was measured using recombinant MLCK 
as substrate, implying that activation of AMPK might regulate MLCK in a feedback mechanism. 
To examine such a pathway, we used STO609 compound, an inhibitor of CAMKK-β, the 
upstream activator of AMPK. Our theory was that if there is a feedback inhibition of MLCK by 
AMPK, then blockade of AMPK activation by STO609 should reverse this inhibition and further 
augment the activity of MLCK. ACh-stimulated AMPK was blocked by STO609, which is 
consistent with the fact of CAMKK-β-dependent activation of AMPK. Most importantly, 
143 
blockade of AMPK augmented ACh-stimulated MLCK activity selectively in antrum without 
changing its activity in fundus. These results imply that in antrum muscle of the stomach, MLCK 
activity is rapidly terminated via a feedback mechanism involving phosphorylation and activation 
of the highly expressed AMPK. Furthermore, measurements of muscle cell length via scanning 
micrometry showed that contraction in response to ACh was enhanced in the presence of STO609 
in anrum, but not fundus.  This is again consistent with the augmentation of MLCK activity by 
AMPK inhibition in antrum.   
Moreover, our data clearly show that stimulation of AMPK activity is Ca
2+
/CaM-
dependent. Using either the calmodulin antagonist, calmidazolium, to inhibit the calmodulin-
regulated activity of CaMKK-β or BAPTA, to chelate intracellular Ca2+ abolished both ACh- and 
KCl-stimulated AMPK activity in antrum without an effect in fundus (as both ACh- and KCl-
induced AMPK activity was minimum in fundus). These results suggest that CaMKK-β is main 
upstream activator of AMPK in smooth muscles of antrum. In addition, both Ca
2+
 influx and Ca
2+ 
release from intracellular stores seem to be important for CaMKK-β-mediated AMPK activation 
as both KCl-induced membrane depolarization and ACh-stimulated m3 receptor activation 
resulted in a significant increase in AMPK activity in antrum. 
In addition, AMPK activation was found to trigger cADPR-dependent SR Ca
2+
 release via 
RyRs in isolated pulmonary arterial smooth muscle cells by yet unknown mechanism
138-140
. This 
effect might be of relevance in longitudinal smooth muscles where cADPR-dependent SR Ca
2+
 
release via RyRs seems to be important especially in the intestine
26
. 
Our MLCK activity data looks contradictory to the ones of Gong et al., in which they 
found that guinea pig ileum and portal vein smooth muscles, which represent phasic muscles, 
have approximately threefold higher activity of MLCK than rabbit femoral artery smooth 
muscles, which represents tonic muscles
141
. Knowing that other non-muscle components and 
144 
regulators might affect enzyme activity in the whole tissue homogenates, MLCK activity 
measured in those tissue samples could be different than our measurements in dispersed smooth 
muscle cells. In addition, differential expression and regional distribution of AMPK isoforms 
could be different in these various smooth muscle organs.  
Other signaling components might add to the above mentioned differences regarding the 
regulation of MLCK in tonic versus phasic smooth muscles. For example, CaM-dependent kinase 
II (CAMKII) protein expression was found to be higher in proximal colon, which represents 
phasic smooth muscles, than in fundus 
142
. CAMKII might regulate smooth muscle contraction by 
phosphorylating several substrates such as MLCK
143
 and phospholamban, a negative regulator of 
sarcoplasmic reticulum Ca
2+
-ATPase 
144
. CAMKII expression profile seems to be in parallel with 
the results of Goyal and his coworkers who found the total content and concentration of CaM to 
be higher in the phasic esophageal body compared to the tonic lower esophageal sphincter
99
. 
These findings might be of more relevance to other CaM-binding proteins such as caldesmon and 
calponin, which we found to be higher in antrum compared to fundus.  
In summary, higher expression of AMPK and greater AMPK-mediated inhibition of 
MLCK in antrum is correlated with rapid contraction and relaxation cycles in antrum (figure 33). 
This observation may be applicable to other phasic smooth muscles 
23,145
. Future studies should 
be directed towards identifying the relative and the regional importance of these regulatory 
pathways in smooth muscle contraction. 
8.3       Differences in the regulation of MLCP activity and muscle contraction 
Phosphorylation of MLC20 by MLCK is counterbalanced by its dephosphorylation by 
myosin light chain phosphatase (MLCP), an essential step in smooth muscle relaxation
141
. MLCP 
is a holoenzyme consisting of three subunits: a catalytic subunit that is a 38 kDa-type I-protein 
145 
phospatase delta isoform (PP1cδ) and two regulatory subunits consisting of a small 20 kDa 
subunit and a 110- to 130-kDa subunit (myosin phosphatase target subunit 1, MYPT1). The 
interactions of the three subunits are required to form the functional enzyme. MYPT1 subunit 
contains a PP1c-binding motif occuring at the amino acids 35-38, followed by seven NH2-
terminal ankyrin repeats. Binding of PP1Cδ with MYPT1 alters substrate specifity and enhances 
catalytic activity. 
MLCP content and activity have been reported to be higher in phasic muscles of ileum, 
portal vein, and gizzard than in tonic muscles of femoral artery and aorta 
141,146
. Others have also 
reported higher basal levels of MYPT1 in the predominantly phasic rectum smooth muscle 
compared to the internal anal sphincter 
147
. Relatively higher content and activity of MLCP in 
phasic smooth muscles may contribute to the lack of steady-state MLC20 phosphorylation and 
basal muscle tone. The lack of basal tone in these muscles might be of relevance to the proposed 
role and behavior of these smooth muscle types where accelerated rate of MLC20 
dephosphorylation and rapid initiation of relaxation is required 
23,141,145
.  
Phosphorylation of the MYPT1 is thought to regulate the activity of MLCP. The major 
regulatory phosphorylation sites of MYPT1 are Thr
696
, Thr
853
, Ser
695
. Phosphorylation of Thr
696
 
in MYPT1 by Rho kinase dissociates the enzyme from PP1cδ and inhibits the activity of the 
catalytic subunit of MLCP. Phosphorylation of Thr
853
 by Rho kinase within the myosin-binding 
domain on MYPT1 dissociates the enzyme from myosin and decreases the efficiency of the 
enzyme by decreasing availabilty of the substrate. While Rho kinse can phosphorylate both Thr
696
 
and Thr
853
, several other kinases have also been shown to phosphorylate the Thr
696
 site such as 
ZIPK.  
 In addition to the inhibitory role of MYPT1 phophorylation at the Thr
696
 and Thr
853
 sites, 
MLCP inhibition can occur via PKC- or arachidonic acid-mediated pathways. Phorbol ester- or 
146 
DAG-mediated activation of PKC, mainly PKC-δ and PKC-ε, 38 results in phosphorylation of the 
17 kDa PKC-potentiated inhibitor protein (CPI-17), at Thr
38
. This phosphorylation significantly 
increases the binding affinity of CPI-17 to the catalytic PP1cδ subunit of MLCP leading to 
dissociation of the holoenzyme and thus inhibition of the  catalytic activity 
148
. Arachidonic acid 
activates both Rho kinase and PKC,  and sphingosylphosphorylcholine (SPC) has also been 
suggested to directly activate Rho kinase
149
. MLCP inhibition by either PKC or Rho kinase is 
thought to be the general mechanism for G-protein-dependent elevation of MLC20 
phosphorylation level and thus maintaining contraction at constant [Ca
2+
]i; a process called Ca
2+
 
sensitization.  
On the other hand, phosphorylation at the Ser
695
 site of MYPT1 by PKA or PKG blocks 
the ability of Rho kinase to phosphorylate the nearby Thr
696
 and thus increases MLCP activity. 
Moreover, PKA and PKG can indirectly augment MLCP activity through phosphorylating and 
thus enhancing the acivity of telokin.  Telokin is an endogenous 17 kDa activator of MLCP.  It is 
a smooth muscle specific protein that is independently and invariably expressed in different 
smooth muscles from a promoter located within an intron of MLCK gene and is thus identical to 
the C-terminus of MLCK downstream from the kinase and calmodulin binding domains.  The 
ability of telokin to stimulate MLCP is moderately enhanced upon phosphorylation of Ser
13
 by 
PKA or PKG. 
Our results demonstrate characteristically higher levels (both protein and mRNA) of Rho 
kinase II-the most common isoform of Rho kinase involved in smooth muscle contraction
130,150
 
and CPI-17, in the smooth muscles of the fundus compared with the antrum.  Our results are 
consistent with the previous studies, which showed higher levels of RhoA/Rho kinase pathway 
and CPI-17 in the internal anal sphincter, which represents tonic smooth muscles, compared with 
the predominantly phasic rectal smooth muscle 
147
. It is of interest that Woodsome et al. 
151
 also 
147 
reported higher levels of CPI-17 in the tonic smooth muscle of the femoral artery than in the 
phasic smooth muscle of the vas deferens.  In addition, our data showed that both protein and 
mRNA contents of ZIPK were similar in both stomach regions.  However, stimulation of ZIPK 
activity was greater in antrum compared to fundus reflecting higher expression and activation of 
upstream kinase, Rho kinase.  
To functionally elucidate the singular contribution of CPI-17 in the muscle contraction, 
we used the PKC activator, PMA. We found that treatment of dispersed muscle cells with PMA 
caused significantly, 2 to 3 folds, greater contraction in muscle cells from fundus than in muscle 
cells from antrum.  In contrast, the extent of PKC activation by PMA was similar in muscle cells 
from both antrum and fundus.  Knowing that CPI-17 is a downstream target of PKC, these results 
correlate well with the higher expression of CPI-17 in the fundus compared to the antrum. Future 
knockout and siRNA studies might further confirm CPI-17 role in MLCP inhibition and thus 
muscle contraction in response to contractile agonist, which activate both Rho kinase/MYPT1 
and PKC/CPI-17 pathways. 
Moreover, our results demonstrated that ACh-induced stimulation of both Rho kinase and 
ZIPK was significantly higher in muscle cells from fundus compared to antrum. Data are also 
consistent with the concept that RhoA/Rho kinase components (responsible for the inhibition of 
MLCP and sustained elevated levels of p-MLC20), are higher in tonic than phasic smooth 
muscles. These results also clarify the relationship between the functional status and the levels of 
these different signal transduction proteins in the tonic versus phasic smooth muscles in their 
basal state in support of previous studies demonstrating constitutive activation of Rho kinase 
pathway in tonic muscle under physiological conditions
152-154
. 
148 
Low levels of RhoA/Rho kinase may unleash MLCP, causing rapid dephosphorylation of 
p-MLC20, preventing the development of any basal tone, and causing rapid fade of stimulated 
contraction in phasic smooth muscles such as the antrum 
155
. This data collectively show that 
fundus is characterized with the molecular apparatus designed to provide sustained levels of 
MLC20 phosphorylation responsible for the basal tone. 
Interestingly, upon treating muscle cells with Y27632, a selective blocker of Rho kinase, 
both Rho kinase and ZIPK activities were inhibited, suggesting that stimulation of ZIPK activity 
is dependent on and downstream of Rho kinase and this might explain the higher ZIPK activity in 
fundus in spite of similar contents in both antrum and fundus.  Although literature is rich in 
research favoring the roles of both Rho kinase and ZIPK in myosin and MYPT1 phosphorylation 
and thus smooth muscle contraction, still few studies haves considered the possibility that these 
two enzymes may in fact directly interact 
43,156,157
. 
It is now believed that both Rho kinase and ZIPK cause Ca
2+
-independnet contraction in 
smooth muscle cells. In addition, ZIPK in smooth muscle phosphorylates many of the same 
substrates as Rho kinase in vitro, including MYPT1 
43
. Moreover, both kinases show a preference 
for threonine and target similar phosphorylation site consensus sequences, i.e. 3–4 basic amino 
acids +1 or +2 N-terminal to the phosphorylation site 
156
. Consistent with our data, Borman et al., 
found that, in smooth muscle, carbachol-induced activation of ZIPK was sensitive to Y27632 
even though ZIPK is not directly inhibited by this compound in vitro 
43
. 
However, knowing that Rho kinase is largely membrane-bound upon RhoA activation, a 
question being raised is how this membrane-bound kinase can directly phosphorylate MYPT1 
and myosin
158,159
. Morgan and co-workers have shown in their studies that stimulation of isolated 
smooth muscle cells by PGF2α induces a marked change in the localization of MLCP, in which 
MYPT1 is initially phosphorylated in the cytosol and then, MLCP is translocated to the 
149 
membrane where the subunits are dissociated. PP1c returns to the core of the cell while MYPT1 
remains at the membrane location. The isolated PP1c reduces phosphatase activity towards 
phosphorylated myosin and thus decreases MLC20 dephosphorylation 
160
. 
Endo et al., 
157
 demonstrated that transfection of HEK293 cells with constutively active 
RhoA promoted interaction of ZIPK with MYPT1. So, it is suggested that ZIPK is a downstream 
target of both RhoA and Rho kinase signaling, forming a signal transduction module to ultimately 
regulate myosin phosphorylation in smooth muscle. Given the location of active Rho kinase at 
the plasma membrane, mechanisms must exist to translocate ZIPK to the activated Rho kinase. 
One possible mechanism might involve binding to MYPT1 where Rho kinase directly interacts 
with ZIPK via translocation of MYPT1 itself from the cytoskeleton to the plasma membrane. In 
another scenario, ZIPK might act as a soluble Rho kinase target to transduce the signal from the 
cell membrane to the actomyosin cytoskeletal elements within the cytoplasm. 
In summary, our studies identified a strong correlation between higher levels and 
activities of Rho kinase/ZIPK/MYPT1 and CPI-17/PKC pathways and tonic phenotype of fundus 
muscle.  These studies combined with the previous studies in different sphincteric muscles in 
several species suggest a pivotal role for MLCP inhibition via Rho kinase/ZIPK/MYPT1 and 
CPI-17/PKC pathways in the maintenance of MLC20 phosphorylation and muscle tone (figure 
33).  
8.4       Differences in the regulation of MLCP activity and muscle relaxation 
On the other side of MLCP regulation, telokin has been shown to activate MLCP and to 
be important for cGMP-mediated calcium desensitization and thus relaxation of smooth muscle 
tissues 
161
. Our data demonstrating higher expression of telokin in antrum compared to fundus are 
in agreement with the previous studies showing higher telokin expression in urinary bladder 
150 
(phasic) compared to aorta (tonic) 
162,163
. Higher expression of telokin and greater activation of 
MLCP and relaxation in antrum compared to fundus is correlated with phasic phenotype of 
antrum.  This is in contrast to the higher expression of CPI-17, an endogenous inhibitor of MLCP 
in fundus.   
To examine the role of telokin in smooth muscle relaxation, contraction was induced by 
Ca
2+
 in permeabilized muscle cells and relaxation in response to 8-Br-cGMP was measured.  This 
approach precludes the effect of 8-Br-cGMP on intracellular Ca
2+
 levels and reflects the effect on 
MLCP probably via phosphorylation of telokin at Ser
13
.  As the response to NO-donor was 
different in antrum and fundus due to differences in the expression of PDE5 and MRP5, 
relaxation in response to 8-Br-cGMP, non-hydrolyzable analog of cGMP, was measured.  Our 
results demonstrated that 8-Br-cGMP, caused significantly greater relaxation in muscle cells from 
antrum compared to fundus.  In contrast, the extent of PKG activation by 8-Br-cGMP was similar 
in muscle cells from antrum and fundus. This relaxation difference between these two muscle 
types is in parallel with the higher telokin expression in antrum.  
These findings were further strengthened by the measurements of MLC20 
dephosphorylation (i.e., MLCP activity) in cells expressing wild type telokin and 
phosphorylation-deficient telokin (telokin S13A) under conditions of where the effects of 
cGMP/PKG on Ca
2+
 levels are precluded as described above. We found that MLC20 
phosphorylation was decreased by the PKG activator 8-Br-cGMP in antrum and fundus, but with 
greater inhibition in antrum.  In addition, the effect of 8-Br-cGMP was attenuated in cells 
expressing phosphorylation-deficient telokin (S13A), and again greater attenuation was found in 
smooth muscle cells from antrum.  Similar levels of MLC20 phosphorylation and contraction in 
response to Ca
2+
 support the notion that telokin action is through the increased activity of MLCP 
rather than inhibition of MLCK activity.  It is noteworthy to mention that the functional 
151 
contribution of telokin to relaxation of Ca
2+
-independent contraction and MLC20 
dephosphorylation has not been determined yet. 
Taken together, our results in antrum and fundus, and those of previous studies in phasic 
visceral and tonic vascular muscle, support the hypothesis that preferential expression telokin and 
increase in MLCP activity contributes to higher relaxation in telokin-rich smooth muscle and 
correlate with the phasic phenotype of the muscle. In contrast, lower expression of MLCP 
activator, telokin, and higher expression of MLCP inhibitor, CPI-17, in tonic muscle facilitate 
greater sensitivity of contractile proteins to low Ca
2+
 levels, a well recognized, but poorly 
understood biochemical characteristic of tonic muscle.  Both mechanisms of MLCP regulation 
may operate in parallel in vivo to restrain MLCP activation and to maintain muscle tone (figure 
33). 
8.5       Differences in the regulation cGMP levels and muscle relaxation.   
The main relaxant neurotransmitters of gastrointestinal smooth muscle are nitric oxide 
(NO), vasoactive intestinal peptide (VIP), and its homologue pituitary adenylate cyclase-
activating polypeptide (PACAP).  These neurotransmitters induce relaxation through generation 
of cAMP and cGMP and activation of PKA and PKG, respectively.  These kinases, in turn, target 
different components of MLCK and MLCP signaling pathways that eventually induce and 
augment myosin light chain dephosphorylation and consequently desensitize the process of 
contraction.   Although generation of both cAMP and cGMP and activation of PKA and PKG are 
the physiological norm, studies in transgenic mice lacking nNOS, sGC, and PKG-Iα suggest that 
cGMP/PKG plays a critical role in relaxation of smooth muscle 
106-108
. 
Cyclic GMP levels in gastrointestinal smooth muscle are well-controlled by the balance 
between the synthetic activities of soluble guanylyl cyclase, and the degradative activities of 
specific PDE5, the main cGMP-specific PDE5 in smooth muscle. Soluble GC is a heterodimeric 
152 
enzyme made up of one α and one β subunit with α1/β1 being the most abundant and the most 
widely expressed isoform of sGC. This isoform was shown to have the most basal and NO-
stimulated activity 
164
. PDE5 is a dimer containing two allosteric cGMP-binding sites in its 
regulatory N-terminal domain and a specific cGMP-binding site in its catalytic C-terminal 
domain that hydrolyses cGMP.  An increase in cGMP levels not only stimulates PKG, but also 
augments PDE5 activity by allosteric activation via binding to its regulatory domain, and by 
PKG-mediated phosphorylation of PDE5 at a conserved serine residue in the N-terminal region.  
Beside degradation by phosphodiesterases, cyclic nucleotides elimination via MRPs-
mediated active export into the extracellular space has been found to be an important pathway in 
returning cyclic nucleotide levels back to basal state. MRP5 mRNA has been detected in various 
smooth muscle tissues with high transcript levels and has been shown to be competent in the 
transport of cGMP. This is supported by the observation that in cerebral cells and platelets, and 
after stimulation with NO, cGMP accumulation is decreased faster than it could be explained 
solely by the phosphodiesterase activity 
165
. Cyclic GMP secretion via MRP5 has been shown to 
be unidirectional and energy dependent 
72
. Studies, using immunofluorescence microscopy, have 
shown that MRP5 is co-expressed with PDE5 in smooth muscle cells, providing a strong 
evidence that these two pathways might complement with each other in keeping cGMP levels 
within a low range 
166
. Thus, the strength and duration of cGMP signaling depends on the activity 
sGC, PDE5 and MRP5.    
Our studies demonstrate higher expression of PDE5 and MRP5 in fundus compared to 
antrum.  As a result, intracellular cGMP levels and relaxation in response to NO-donors were 
attenuated more in fundus compared to antrum (figure 34).   Increased degradation and efflux of 
cGMP might play an important role in rapid termination of relaxation in fundus.   Relaxation of 
tonic smooth muscle in response to NO is transient and the muscle regains contraction to prevent 
153 
continuous distending forces or reflux of materials.  At the tissue level, non-muscle elements add 
more complexity to the above mentioned biochemical differences in cGMP handling between 
phasic and tonic muscles. For example, it was found that the density of eNOS positive neurons 
was scarce in fundus part of the human stomach while their density in distal part was intensive 
167
.Thus it is possible that in addition to increase in the termination of cGMP signaling, the 
mechanisms responsible for generation of cGMP such as generation of NO and activation of sGC 
are also constrained in fundus to facilitate tone and optimal organ function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
Figure 35. Differential expression and/or activation of signaling proteins involved in the 
regulation of MLC20 phosphorylation in antrum and fundus of stomach correlate with the 
phasic and tonic smooth muscle phenotypes, respectively. Signaling proteins shown in red 
are involved in phasic phenotype and those shown in green are involved in tonic phenotype; + 
and – signify stimulation and inhibition, respectively. 
Antrum: Higher expression of AMPK and selective feedback inhibition of MLCK activity via 
AMPK-mediated phosphorylation, and higher expression of telokin and activation of MLCP 
correlate with the rapid cyclical contractile function in phasic muscle. 
Fundus: Higher expression and activation of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17 
pathways leading to preferential inhibition of MLCP activity and sustained phosphorylation of 
MLC20 correlate with the sustained contraction in tonic muscle. In addition, rapid termination of 
cGMP signal and thus, muscle relaxation by degradation and efflux of cGMP via higher 
expression of PDE5 and MRP5, respectively, facilitate rapid restoration of tone. 
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